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Abstract
Severe cases of influenza A virus (IAV) infection are often complicated by concomitant
bacterial pneumonia or sepsis. Many bacterial species are capable of producing potent
immunomodulators called superantigens (SAgs), which have the potential to interfere with
cell-based antiviral immune mechanisms. I asked what effects bacterial SAgs have on both the
magnitude and the breadth of antiviral CD8+ T cell (TCD8+) responses. Surprisingly,
administration of SAgs to mice shortly before or after vaccination with IAV increased the
number of primary TCD8+ responding to select IAV-derived epitopes. T cell receptor staining
of these SAg-augmented populations revealed expression of Vβ regions that bind SAgs. In vivo
evaluation of the cytotoxic capability of these cells revealed increased killing of target cells
pulsed with viral peptides. Memory TCD8+ specific for IAV were also expanded by certain
SAgs and displayed increased effector functions, though the effect of SAgs on TCD8+ recall
depended critically on the timing of SAg injection relative to priming and boosting inoculation
of IAV. Though SAg exposure did not augment local pulmonary TCD8+ responses to active
IAV infection, it also did not impair these responses as measured by the effect on weight loss
and viral titre. Finally, I show that SAg-induced augmentation of the magnitude, breadth and
function of IAV-specific memory TCD8+ can be recapitulated in in vitro experiments utilizing
human cells. This work elucidates an unexpected role for bacterial SAgs as potential enhancers
of antiviral immunity in the context of TCD8+-based vaccination strategies.
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Chapter 1: Introduction
1.1 Host responses to infection
The mammalian immune system has evolved to provide effective protection against a wide
array of bacteria, parasites and viruses. The components of the immune system are divided
into two main arms, though there are some types of immune cells with characteristics of
both. The innate arm of the immune system is fast-acting but non-specific, or polyspecific
at best, offering protection against pathogens by recognizing evolutionarily-conserved
molecular motifs associated with infection or danger signals (1). Adaptive immunity takes
longer to develop, but is highly specific and capable of eliminating pathogens and provides
long-term memory against future infections (2). Both arms of the immune system are often
necessary for protection against pathogens.

1.1.1 Innate immunity
The cells of the innate immune system are the first line of defence against infection by
pathogenic organisms. Overall, the role of innate immunity is to keep infections in check
and prime the adaptive immune system for a more targeted response. Another defining
feature of the innate response is that it does not typically exhibit memory; that is, the
magnitude of the response to a given immunological insult is usually equivalent regardless
of prior exposures.
The components of the innate immune system recognize molecules that are associated with
pathogens or other immunological insults. These pattern recognition receptors (PRRs)
recognize conserved microbial molecules (pathogen associated molecular patterns, or
PAMPs) and other danger signals that are present in the body soon after infection and are
the same in every individual of a given species (3). Perhaps the most well-known of these
components are Toll-like receptors (TLRs) that are found as dimeric proteins expressed by
some innate immune cells. TLRs recognize certain types of molecules derived from
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pathogens; for example, TLR4, in collaboration with CD14, recognizes the presence of
bacterial lipopolysaccharide (LPS) and activates intracellular signalling cascades leading
to the activation of the innate immune system (4). In the same vein, nucleotide
oligomerization domain (NOD)-like receptors (NLRs) survey the intracellular environment
for microbial products and other danger-associated signals (5). Many other types of PRRs
exist, but all function to recognize danger to the host and to mobilize the immune system
to deal with the threat.
The innate immune system also includes cells that are capable of quickly responding to
and eliminating pathogens. The first innate immune cells to respond to infection are often
neutrophils, which are short-lived but abundant phagocytic cells. They respond to an
infection by phagocytosing pathogens and producing toxic mediators to control infection
(6). Macrophages are able to efficiently phagocytose targets and produce chemokines that
attract other immune cells to the site of infection (7). Innate immune cells are also capable
of recognizing and responding to the absence of markers that should be expressed on a
normal cell. Natural Killer (NK) cells look for missing ‘self’ signals on the surface of host
cells, which can be indicative of abnormal function (such as cancer) or viral infection. NK
cells can then lyse the abnormal target cell through the secretion of perforin and granzymes
(8). In addition to the functions mentioned above, the innate immune system is also
responsible for activating the adaptive arm of immunity. Dendritic cells (DCs) link the two
arms by taking up extracellular material and presenting processed antigens to certain cells
of the adaptive immune system. By presenting antigen to the appropriate cell type and by
expressing costimulatory molecules they serve as the bridge between the innate and
adaptive arms of the immune system (9).

1.1.2 Adaptive immunity
The distinguishing features of the adaptive arm of the immune system include a fine
specificity and capacity for memory. Unlike innate immunity, the adaptive system requires
several days after initial antigen contact before mounting an effective response. Adaptive
immune cells are able to recognize specific pathogen-derived peptides and eliminate their
targets while causing less collateral damage than the more general targeting of the innate
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immune arm. Adaptive immune responses also generate immunological memory, resulting
in the generation of long-lived cells that are capable of rapid activation upon encountering
the same antigen. These secondary responses quickly eliminate pathogens before they have
the chance to cause damage to the host. Adaptive immunity is typically separated into two
branches, each necessary for effective immunity.

1.1.2.1 Humoral response
The main cellular components of the humoral immune system are B cells, which largely
exert their effector function through the production of antibodies specific for given
antigens. B cells arise from common hematopoetic stem cell precursors in the bone
marrow. The genes that encode segments of the B cell receptor (BCR) are rearranged
independently on a per-cell basis, such that each B cell has a BCR specific for a unique
epitope. Immature B cells first express surface immunoglobulin of the IgM isotype before
adding surface IgD expression after exiting the bone marrow. These mature but antigeninexperienced B cells circulate through the lymph nodes and the lymphatic system until
they encounter their cognate antigen (10).
Upon cognate antigen encounter, B cells upregulate adhesion molecules such as
lymphocyte function-associated antigen 1 (LFA-1), which causes them to migrate to
secondary lymphoid tissues such as the spleen and lymph nodes (11). However, the vast
majority of B cells typically find their cognate antigen when circulating through the
secondary lymphoid tissue itself. After antigen encounter in the spleen or lymph nodes, B
cells will traffic to the red pulp or primary lymphoid follicle, respectively. They will then
proliferate to form a primary focus in the spleen or a germinal center in the lymph node.
The entire process, from antigen encounter to proliferation, takes about five days to
complete (12).
Within the germinal center the proliferating B cells undergo class-switching and somatic
hypermutation (SMH). Class switching involves the splicing of the epitope-specific Vregion of the B cell receptor DNA and ligation to a new C-region, which changes the
isotype of the antibody that the cell produces. B cells start out by producing exclusively
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IgM molecules, but after class-switching they may gain the ability to produce IgA, IgE or
IgG. SMH can occur at the same time as class-switching and involves the creation of single
point mutations in the V-region of the immunoglobulin heavy and light chains. This
process, known as affinity maturation, produces many B cell clones with a lower affinity
for the target epitope and a few clones that have a higher affinity. The clones with lower
affinity die by apoptosis due to lack of antigen binding, while the higher affinity clones are
positively selected for and continue to proliferate. This whole process results in B cells that
produce antibodies with a higher affinity for the target antigen than the original clone. The
surviving, high-affinity B cells then continue to proliferate and differentiate into plasma
cells, which secrete large amounts of antibody to deal with the infection, or long-lived
memory B cells that continue to reside in the lymph node (13).
If the host then re-encounters the pathogen that the memory B cell response was developed
against, the memory B cells are quickly re-activated and differentiate into plasma cells,
which produce large amounts of high-affinity antibody. This rapid antibody production
after secondary exposure requires a much lower dose of antigen than the primary response
(14), eliminating the pathogen much more quickly. The production and maintenance of an
antigen-specific pool of memory B cells is the end goal of many different vaccination
protocols (15).

1.1.2.2 Cell-mediated response
T cells are the main players in the cell-mediated arm of the adaptive immune system. Like
B cells, they arise from common lymphoid progenitors in the bone marrow. Unlike B cells,
T cells must traffic to the thymus and receive the appropriate signals from the thymic
stroma before they can mature (16). T cell progenitors in the thymus first undergo
rearrangement of their germline V, D and J regions to generate a unique T cell receptor
(TCR) (17). This process, known as V(D)J recombination, involves the cutting and pasting
together of different gene segments. Though there are only a set number of V, D and J
segments available for recombination, TCR diversity is greatly increased by the action of
terminal deoxynucleotidyl transferase (TdT), which adds strings of random nucleotides to
the junctions of the different gene segments. In this way, the potential number of unique
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TCRs in a given individual can exceed 1015 (18). T cell clones that successfully complete
V(D)J recombination enter the double positive stage, characterized by the simultaneous
surface expression of CD4 and CD8. The cells then undergo positive and negative
selection, which eliminates clones that are unable to bind self-major histocompatibility
complex (MHC) with sufficient affinity or recognize self-derived peptides. Though 98%
of T cell precursors are eliminated by this point, those that have survived become either
single-positive CD4+ (TCD4+) or CD8+ T cells (TCD8+) before travelling to secondary
lymphoid organs to await encounter with their cognate antigen (19).
T cells are activated upon TCR-mediated recognition of cognate peptides presented in the
context of MHC I (for TCD8+) or MHC II (for TCD4+). Optimal activation requires the
presence of the appropriate costimulatory molecules on antigen-presenting cells (APCs),
as well as the presence of appropriate cytokines (20, 21). The combination of these three
signals results in the induction of intracellular signalling pathways within the T cell,
stimulating proliferation and initiation of effector functions. Though several different types
of T cells (differentiated by the composition of their TCR and ultimate effector function)
exist, the most common and most extensively studied are CD4+ and CD8+ αβ T cells.
The main function of TCD4+ is to provide help to B cells and macrophages. CD4+ T cells
provide help to their cognate B cells, allowing them to survive, proliferate, and secrete
antibody. In addition, TCD4+ can be influenced by the cytokine milieu to acquire a Th1 or
Th2 phenotype (22). Th1 responses are classically marked by the production of
inflammatory cytokines such as interferon (IFN)γ, which are helpful during immune
responses against intracellular pathogens and cancerous cells. Th2 responses are
characterized by the production of interleukin (IL)-4, IL-5 and IL-13, which are helpful
during antibody responses against extracellular pathogens such as most bacteria and
parasites (23, 24, 25). Activated TCD8+ are responsible for finding and killing target cells
that express their cognate antigen. Typically, TCD8+ antigens are derived from intracellular
peptides that can originate from the host or from pathogens inside the cell (26). Almost all
cell types express MHC I, which serves as a monitoring system to ensure that the cell is
not infected by viruses or producing any abnormal peptides. If an activated TCD8+
recognizes its cognate peptide presented in the context of MHC I on the surface of a cell,
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the TCD8+ will bind MHC I through its TCR and induce target cell death through one of
several pathways. These include Fas/FasL interaction, activation of the TNF-related
apoptosis-inducing ligand (TRAIL) pathway, tumour necrosis factor (TNF)α production,
and induction of the perforin/granzyme pathway (27, 28, 29). After resolution of the
immunological insult, a subpopulation of the epitope-specific TCD8+ remain as long-lived
memory cells that rapidly proliferate and differentiate into cytotoxic effector cells upon reencounter with antigen.

1.1.2.3 Antigen processing and presentation
Integral to the initiation of an adaptive immune response is the processing and presentation
of protein antigens (Ags) from pathogens or abnormal host cells. Antigen processing and
presentation can be divided into two general categories depending on whether the Ag
originates from inside the antigen-presenting cell (APC) or from outside the cell. In
general, antigens from extracellular sources or from cellular vesicles are presented on MHC
II molecules for presentation to CD4+ T cells, while antigens arising from the cytosol of a
cell are processed through a different pathway for loading onto MHC I and eventual
presentation to CD8+ T cells (30).
The generation of peptides for presentation on MHC II relies on the endocytosis of
extracellular pathogens by APCs such as macrophages, activated B cells and dendritic
cells. MHC II molecules are located in the endoplasmic reticulum (ER), where they are
loaded with a class II-associated invariant-chain peptide (CLIP) to prevent promiscuous
binding to other host peptides that may be present in the ER. The MHC II molecule resides
in an acidified endosome, which can fuse with other vesicles containing material that has
been obtained from outside the cell. These vesicles contain peptides derived from the
breakdown of extracellular proteins, which is mediated by low pH and the action of
proteases. In order to successfully bind MHC II the peptides need to be 15-24 residues
long, as shorter or longer peptides do not form a stable complex (31). However, before
these pathogen-derived peptides can bind the MHC II molecules, they must release CLIP.
This is achieved by the class II-like molecule HLA-DM, which binds to the MHC II:CLIP
complex, thus dissociating CLIP from MHC II. The endosomal pathogen-derived peptides
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are subsequently able to bind the MHC II’s peptide binding groove, which allows
translocation of the MHC II:peptide complex to travel to the cell surface. MHC II is
typically only expressed by APCs, as the presentation of MHC II antigens activates CD4+
T cells, which can help B cells to secrete antibody and activate macrophages to eliminate
extracellular threats.
The MHC I pathway is geared towards the processing and presentation of antigens obtained
from the cytosol. Proteins present in the cytosol are degraded by the immunoproteasome
(32), which preferentially produces peptides that are of the right length (8-11 residues) to
fit in the peptide-binding pocket of MHC I (33). These peptides are then delivered from
the cytosol to the ER by transporters associated with antigen processing (TAP) 1 and 2
molecules, where they can be loaded onto MHC I molecules. MHC I is retained in the ER
in a partially folded state stabilized by calnexin until binding of β2-microglobulin. The
MHC I complex is then released from calnexin to bind calreticulin and tapasin, which
brings the complex into close proximity with TAP. Upon peptide loading, the MHC I
complex is stabilized and transported to the cell surface. All nucleated cells express MHC
I and present cytosol-derived peptides as a form of immune surveillance for cancerous cells
and intracellular infection. Thus, cells that display pathogen-derived peptides on MHC I
are killed by cognate CD8+ T cells. Furthermore, any cell that does not express MHC I and
displays activating receptors for NK cells will be lysed by NK cells (34), though there are
exceptions to this rule. For example, erythrocytes express inhibitory receptors along with
CD47 as an alternative marker of “self” (35).

1.1.2.3.1 Cross-Presentation and Cross-Priming
In some cases, MHC I molecules can present peptides to TCD8+ cells derived from
extracellular sources. This is known as cross-presentation and is important for the TCD8+
response to certain viruses and cancers (36). DCs have the ability to phagocytose
extracellular material such as dead or dying cells that may contain proteins derived from
viruses. The extracellular material is then transported from the phagosome to the cytosol
where it can be degraded by the immunoproteasome, transported via TAP into the ER and
subsequently loaded into MHC I molecules for presentation to naive CD8+ T cells. In this
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case, the presenting DC is not immediately killed by the TCD8+ cell. Rather, the formerly
naive TCD8+ becomes an effector cell and is induced to search out and destroy host cells
that present its cognate peptide in the context of MHC I. This is important for the activation
of naive TCD8+ by dendritic cells, as not all viruses can infect APCs (37, 38). In addition,
cross-priming is important in cancers where the tumour cells fail to express MHC I yet
escape killing by NK cells (39, 40).

1.2. Immunopathology caused by bacterial infections
Though the immune system has evolved to be indispensable for human health, some
pathogens are capable of skewing the components of the immune system towards a harmful
response. This can be achieved through multiple mechanisms, from formation of harmful
antigen and antibody complexes to direct activation of immune cells by bacterial toxins or
by inflammatory bacterial products.

1.2.1 Infection by Gram-positive bacteria
Gram-positive bacteria are so-called because of their thick cell wall layers of
peptidoglycan, which retain the crystal violet component of the Gram stain mixture in
contrast to Gram-negative organisms, which are only stained by the safranin component.
Current common Gram-positive infections include those caused by Streptococcus and
Enterococcus species, with an increasingly prominent role being played by multiple-drug
resistant species of Staphylococcus (41).

1.2.1.1 Staphylococcus aureus infections
Staphylococcus aureus is a common bacterium that asymptomatically colonizes roughly
30% of the human population (42). S. aureus can cause disease in a myriad ways depending
on the expression of different virulence factors by the bacterium and the route of entry into
the body. Most infections with S. aureus occur in the skin and soft tissue, with more than
one million cases in the United States requiring medical intervention (43). More serious,
life-threatening diseases caused by S. aureus include toxic shock syndrome, sepsis and
endocarditis. In the context of these diseases, S. aureus has the ability to induce extensive
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immunopathology. It is known to be able to survive inside neutrophils, which protects the
bacteria from killing by other immune cells (44). S. aureus has also been shown to exploit
this ability to survive inside highly mobile immune cells such as macrophages, using them
as vehicles for dissemination into other tissues (45). Secreted toxins such as α-hemolysin
and Panton-Valentine leukocidin promote lysis of innate immune cells such as monocytes
and neutrophils, disrupting the immune response while catalyzing the release of additional
inflammatory signals (in the form of dead cells and debris) that can result in tissue damage
(46).

1.2.2 Bacterial superantigens
A major mediator of bacterial infection-induced immunopathology is the action of a class
of proteins known as superantigens (SAgs). The most well-studied SAgs are those
produced by S. aureus and S. pyogenes; SAgs from both species of bacteria function in a
similar way. Mycoplasma arthritidis can also produce a SAg called Mycoplasma arthritidis
mitogen (MAM), though this has received less attention as M. arthritidis is not a human
pathogen (47). SAgs tend to be small secreted proteins that are remarkably stable, with
some resistant to denaturation after desiccation and boiling for short periods of time (48).
Their defining feature is the ability to activate large numbers of T cells to proliferate and
secrete inflammatory cytokines (49). In vivo, this results in a cytokine storm, which has
been implicated in the pathogenesis of diseases such as bacterial sepsis and toxic shock
syndrome (50). Bacterial SAgs also have potential as agents of bioterrorism, notably
through induction of a fatal respiratory reaction after inhalation (51).
SAgs from S. aureus and S. pyogenes function through similar mechanisms. They both
bind the lateral surface of the human MHC II molecule and the Vβ region of CD4+ and
CD8+ TCRs, cross-linking the two molecules together regardless of the peptide occupying
the peptide-binding groove (52, 53). This causes activation of the T cell, resulting in
vigorous proliferation and secretion of inflammatory cytokines. In this manner up to 30%
of all T cells in a given individual may be provoked to proliferate (50). The fate of these T
cells after activation is controversial and may depend on the activation state of the cell
before contact with the SAg. Most previous research suggests that T cells activated by
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SAgs are eliminated through activation-induced cell death, or become anergized through
the lack of appropriate costimulation by APCs (54, 55). However, other studies using
different methods to assess the fate of antigen-specific T cells and different timepoints after
SAg administration indicate that this may not be the case (56). TCR internalization is one
outcome of T cell activation and this has complicated investigations into the effects of
SAgs (57). In addition, SAgs have different Vβ binding profiles; that is, different SAgs can
bind to only a few different Vβ regions out of the 60 or so that are expressed in humans.
For example, staphylococcal enterotoxin B (SEB) is known to bind to Vβ 1, 3, 6.4, 7, 12.2,
13.2, 14, 15.1, 17.1 and 20, while toxic shock syndrome toxin-1 (TSST-1) predominantly
binds Vβ 2.1 (58).
SAgs derived from S. aureus are of particular interest because of their multifarious roles in
human disease. S. aureus encodes a number of superantigenic enterotoxins, so named
because of their implication in instances of foodborne illness. Ingestion of less than 1 μg
of SEB in contaminated food is sufficient to induce cramping, diarrhea and vomiting within
four hours of eating contaminated food (59). Staphylococcal SAgs are also the main
inducers of the cytokine storm accompanying TSS and sepsis, which is predominantly a
result of the massive release of TNFα, IL-2 and IFNγ, with a crucial role also being played
by IL-17 (60, 61). S. aureus is also the pathogen responsible for perhaps the most wellknown instance of SAg-mediated disease. In the 1970s, there was an outbreak of menstrual
toxic shock syndrome (TSS), which was later traced to the use of high-absorbency tampons
that encouraged the growth of S. aureus (62, 63). The incidence of menstrual TSS
plummeted after these tampons were phased out, but non-menstrual TSS was and continues
to be a public health problem (64). In cases of non-menstrual TSS caused by S. aureus the
SAgs that are responsible for pathogenesis are staphylococcal enterotoxins A, B and C
(SEA, SEB and SEC) (65). There is currently no good treatment for SAg-mediated
systemic diseases such as TSS or sepsis besides supportive care.

1.3. Immunopathology caused by viral infections
Many viral species are also capable of inducing immunopathological responses as a side
effect of infection. In some cases the virus can take advantage of the immunopathological
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reaction to increase the production of viral particles, while in other cases it is deleterious
to both the virus and the host. The following section will briefly cover some examples of
virus-induced immunopathology, with a special focus on influenza A virus (IAV).

1.3.1 General overview of virally-induced immunopathology
Viral infection can be characterized as either acute or chronic; that is, replicating for a short
period of time in the host before clearance by the immune system (or death of the host), or
persisting for an indeterminate length of time due to evasion or disruption of host immune
responses. Both viruses that cause acute infections and viruses that cause chronic infections
can induce immunopathology. Hepatitis C virus (HCV) is an example of a virus that causes
a chronic infection accompanied by CD8+ T cell-mediated destruction of bystander
hepatocytes, which can result in cirrhosis of the liver (66). Hepatitis B virus is another
chronic pathogen that instigates an immunopathological response. Antibodies generated
against this virus can form complexes with viral particles, which then become trapped in
dense capillary beds such as those found in the kidney (67). This induces aberrant
activation of the complement cascade, resulting in tissue damage and potential loss of
organ function. Acute viral infections can also be potent inducers of immunopathological
reactions. One interesting case is that of Dengue virus, which can induce immunopathology
through molecular mimicry. In mouse models it was found that the viral NS1 protein
induces the generation of IgM antibodies that cross-react with host platelets (68). This
results in thrombocytopenia and the subsequent hemorrhage that characterizes severe cases
of Dengue infection. Another acute virus that can induce a great degree of
immunopathology is IAV, especially the novel pandemic strains that can arise from the
exchange of genetic material between human and animal IAVs. In the most severe cases
IAV can be responsible for the induction of a so-called cytokine storm, which can be
described as a self-perpetuating positive feedback loop largely initiated by the cells of the
immune system in response to infection (69). Infection of airway epithelial cells leads to
the production of type I IFN, which signals to alveolar macrophages and other innate
immune cells, causing them to migrate to the site of infection and release more
inflammatory mediators. The release of these cytokines (notably TNFα) and chemokines
in turn brings in more responding immune cells, which continues to amplify the
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inflammatory signal until it is beyond the ability of anti-inflammatory signals to attenuate.
This sort of positive feedback loop has been shown to occur more often in cases of severe
infection of young, immunocompetent people infected with antigenically novel IAVs (70).
The high propensity of IAV to rapidly change its proteins (i.e. an antigenic shift) makes
this virus of special concern when investigating how the immune system can become
harmful. Antigenic shift events usually presage the development of pandemic strains, as
this process creates IAVs against which the population has no pre-existing immunity (71).

1.3.2 Influenza A virus
Influenza viruses are part of the family Orthomyxoviridae, which together comprise 7
different genera and eight different species of negative-sense RNA viruses. Of these, IAV
is by far the most relevant to public health, as Influenza A virus is a global pathogen,
responsible for more than 500,000 deaths per year worldwide (72). Pandemic strains, which
arise with alarming frequency, have the potential to cause even greater morbidity and
mortality. The most famous of these pandemics, the 1918 Spanish Flu, killed an estimated
50 million people worldwide, eclipsing the mortality arising from the first World War that
it was cotemporaneous with (73). IAVs are named according to a standardized system that
follows the format “species (if non-human)/location of isolation/isolate number/year of
isolation/H and N subtype” (74). For example, strain A/Puerto Rico/8/1934/H1N1 (PR8)
denotes a human IAV strain expressing H1 and N1, isolate number 8 retrieved from Puerto
Rico in 1934.
Clinically IAV infection is characterized by fever, malaise, cough and body aches that
typically resolve in 7 to 10 days (75). Viral titres and shedding peak in the respiratory tract
after about two days, with detectable virus shedding lasting an average of seven days after
infection (76). IAV causes the most morbidity and mortality among the very young as well
as elderly individuals, or those with complicating illnesses or immunosuppression (77).
However, antigenically novel pandemic strains such as the 1918 Spanish Flu
disproportionately affect or affected young, healthy individuals (78). The reason for this is
partially attributable to a cytokine storm-like syndrome induced by overactivation of the
immune system, which will be discussed later (79).
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1.3.2.1 Structure and replication cycle
Structurally, IAV is relatively simple when compared to larger viruses. Most particles of
IAV are spherical and measure about 100 nm in diameter, though filamentous forms can
be over 300 nm in length (74). The host-derived lipid envelope covering the virus is studded
with hemaggluntinin (HA) and neuraminidase (NA) molecules, in addition to the matrix
(M2) ion channel. Underneath the envelope is a layer of M1 protein, which encloses the
virus replication machinery and single-stranded negative sense ribonucleic acid (ssRNA)
genome. The whole genome codes for only 12 proteins, broken up over eight discrete
segments (80). Within the viral core, the viral genomic RNA strands are coated with
nucleoprotein (NP) molecules and associated with an RNA-dependent RNA polymerase.
This polymerase is composed of three different proteins, two polymerase basic subunits
(PB1 and PB2) as well as one polymerase acidic subunit (PA). The viral RNA,
nucleoprotein and polymerase together make up what is referred to as the viral
ribonucleoprotein complex (vRNP) (74).
The viral replication cycle starts with binding of the outer HA protein to the sialic acid
receptor on the host cell surface (81). Human IAV predominantly recognizes sialic acids
bearing α-2,6 – linkages on galactose molecules, which are found in epithelial cells lining
the trachea (82). Upon HA binding, the viral particle is internalized mainly via clathrinmediated endocytic pathways, whereupon it is trafficked from the early to the late
endosome (83). The virus then gains entry into the host cell cytoplasm upon conformational
changes in the viral HA protein induced by the low pH of the endosomal compartment,
allowing fusion of the viral outer membrane with the host endosomal membrane. This
genome release allows the vRNP complex to traffic to the nucleus, where mRNA encoding
viral proteins are synthesized and viral genomic RNA is replicated. After nuclear export,
the newly synthesized viral protein and genomic RNA travel to the host cell membrane
where they are assembled into new viral particles. These particles then bud off from the
infected cell, a process that relies on the sialidase activity of the NA protein to release these
nascent viral particles from the host cell membrane (84). IAV subtype is classified
according to the type of HA and NA molecules expressed on the surface. Currently, there
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are 18 different HA and 11 different NA molecules circulating in the IAV population,
though only a handful of these are found on strains that can infect humans (85).

1.3.2.2 Pathogenesis
IAV is transmitted through airborne particles that are formed as a result of coughing or
sneezing of infected individuals (86, 87). Inhalation of these droplets allows the virus to
reach the upper respiratory tract of a new host to initiate infection. The location of the
epithelial cells in the airway that are infected by IAV influences the pathogenicity of a
given flu strain. Seasonal IAV strains typically infect cells with α2,6-sialic acid linkages,
which in humans are found predominantly in the upper respiratory tract (88). This usually
causes a comparatively mild, self-limiting illness in most healthy individuals. However,
highly pathogenic viruses such as avian H5N1 influenza strains preferentially infect cells
with α2,3-sialic acid linkages, which in humans are found on type 2 pneumocytes deep in
the lung (88). Infection of these cells can result in a serious, sometimes fatal viral
pneumonia (89). In addition, the ability of the HA protein to be cleaved by host proteases
also influences pathogenicity. In order to enter a cell, the HA molecule must first be cleaved
into HA1 and HA2. Highly pathogenic strains of IAV can be cleaved by multiple different
host proteases, increasing the likelihood that the virus will be able to enter the target cell
(90). Ultimately, the main driver of pathogenesis that is directly attributable to the virus is
its ability to induce apoptosis of infected cells. Much of this is attributable to the action of
the PB1-F2 protein, which traffics to and disrupts the inner mitochondrial membrane and
also induces the release of proinflammatory cytokines (91, 92).
Host factors and the host immune response play a major role in the pathogenesis of IAV.
Infection by IAV efficiently induces a type I IFN response as well as activation of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB), which results in the
production of large amounts of inflammatory cytokines and chemokines. In particular, the
C-C motif chemokine ligand (CCL)5 and CCL2 recruit inflammatory macrophages to the
alveoli, which in turn kill alveolar epithelial cells through a TNF-related apoptosisinducing ligand (TRAIL)-dependent mechanism (93). Highly pathogenic strains of IAV
also induce a large influx of neutrophils that can also induce cellular damage, though the
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role of these cells (pathogenic versus protective) is complicated by their important role in
the control of viral titres (94, 95). In the most serious cases of viral pneumonia, the end
result of the excessive epithelial cell damage and release of inflammatory cytokines is
desquamation of the epithelial cell layers, pulmonary edema and the formation of hyaline
membranes (96, 97).

1.3.2.3 Antigenic shift and drift
One of the defining features of IAV is its ability to undergo rapid antigenic change from
year to year, allowing the virus to escape the action of neutralizing antibodies and
necessitating the annual development of a new seasonal flu vaccine formulation. There are
two major mechanisms underlying this antigenic change, known respectively as antigenic
drift and antigenic shift. Both are of concern when developing IAV-specific therapies,
though large antigenic shifts remain the greater concern in terms of global health.
Antigenic drift is defined as the accumulation of point mutations in regions of viral proteins
that are recognized as epitopes by the immune system. In the case of IAV this antigenic
shift is rapid enough to necessitate the development of a new seasonal flu vaccine every
year for the northern and southern hemispheres, and extensive enough to describe IAV as
a collection of quasispecies rather than a single definable virus (98). The main driver of
antigenic drift is evolutionary selection pressure, in that viruses that escape antibodymediated neutralization survive and continue to spread between hosts (99). The mechanism
underlying antigenic drift is the error-prone nature of the IAV RNA-dependent RNA
polymerase, which creates a mutation 1×10-3 to 8×10-3 times per nucleotide per year (100).
The polymerase also lacks exonuclease proofreading capability, therefore errors introduced
during genomic replication are propagated rather than corrected (98). The antibody
response to IAV is largely directed at epitopes in HA and NA. Thus, mutations in antigenic
regions of these proteins that preserve their functional ability will create viruses that have
a selective advantage.
The process of antigenic shift relies on the fact that the genome of IAV is organized into
eight separate segments. It requires the infection of a host cell by at least two different
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IAVs such that the host cell acts as a “mixing vessel” for the genetic information from the
two different strains (101). When the two different IAVs infect the same cell, the viral
material from both strains is released into the cytosol and both viruses replicate their
genetic material. However, since the RNA from both viruses is stored as discrete segments
it is possible for the newly formed virions to package RNA segments that originated from
both viruses. For example, three of the eight segments could be from virus A while five of
the segments could be from virus B. This leads to the production of a strain of IAV that
has the potential to be different antigenically from strains that had previously circulated in
a given species. Swine often act as mixing vessels for human and avian viruses, as pigs
express both α2,6-sialic acid linkages and α2,3 linkages on their airway epithelial cells,
allowing infection by viruses from both species (101). Such recombined viruses, if they
are able to efficiently infect human cells, can give rise to strains of IAV that are
antigenically novel due to the presence of proteins originally confined to avian IAVs.
Antigenic shifts are typically responsible for the rise of pandemic IAVs, as these shifted
viruses have the potential to circulate among populations that have little to no pre-existing
immunity (102, 103).

1.4. Immune responses to influenza A virus
Despite the ability of IAV to rapidly change its antigenic profile, the human immune
system is capable of mounting robust immune responses to the virus. Immune responses to
IAV occur first in the upper respiratory tract and lungs, followed later by the dispersal of
adaptive memory cells to secondary lymphoid tissues such as the spleen and lymph nodes
after resolution of infection. The primary response to IAV is largely mediated by innate
immune cells and TCD8+, while control of secondary infection is achieved through the
action of neutralizing antibodies (104).

1.4.1 Innate immune responses to IAV
The first adaptive immune effector cells reach the lungs 5 days after infection at the earliest
(105). They require the help of the innate immune system for recruitment and activation;
thus, the first line of host defense against IAV is the innate immune response. This consists
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of a variety of physical barriers, antiviral proteins and cells that can act quickly in response
to infection.
In humans, IAV infects the cells of the respiratory tract and, to a lesser extent, the lungs.
Mucus that is naturally found in the airways is capable of trapping viral particles, while the
ciliary beating action of airway epithelial cells transports mucus from the lungs to the upper
respiratory tract (106). Human saliva also contains many chemical inhibitors that are
capable of protecting against IAV, such as the defensins human neutrophil peptide (HNP)
and histatin (107). H-filcolin can also bind IAV to prevent it from binding to sialic acid on
lung epithelial cells, in addition to its complement-fixing ability (108). Deeper in the
airways, other molecules such as surfactant protein-D (SP-D) have also been found to
protect against IAV infection (109). Natural IgM is also present in the lungs and can fix
complement upon binding to viral particles (110).
The sialic acid-expressing airway epithelial cells also have innate defenses that are
activated upon infection with IAV. They can release pre-formed IFNβ in response to
infection, which results in the transcription of genes coding for antiviral proteins (111). In
addition, PRRs expressed by epithelial cells are used to sense infection and activate
antiviral defense pathways as well. TLR3 recognizes double-stranded RNA (dsRNA)
produced during IAV replication, while TLR7 can recognize the ssRNA genome of IAV
(112, 113). Retinoic acid-inducible gene I (RIG-I) and NOD-like receptors can also sense
IAV infection and activate antiviral and inflammatory pathways (112, 114). In humans, the
interferon-inducible MxA protein restricts viral transcription, and the absence of its mouse
analog Mx1 in many laboratory mouse strains is responsible for the high susceptibility of
these animals to IAV-induced morbidity and mortality (115, 116).
Among the first innate immune cells to reach the lungs in response to IAV infection are
neutrophils (117). They secrete many types of antiviral molecules including α-defensins,
which can neutralize many strains of IAV (118). Neutrophils also phagocytose dead or
dying cells, removing them from the airway while simultaneously capturing viral antigen
for presentation (119). This allows neutrophils to act as APCs for the cells of the adaptive
arm of the immune system (120). After being recruited to the lung by the release of IL-15,
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NK cells also play an important role in the control of viral titre (121). However, the key
immune cells in the innate response to IAV are the alveolar macrophages. They are
essential for the control of viral replication in the lungs through their phagocytic activity
and early secretion of cytokines and chemokines (122, 123, 124). They are the major
producers of granulocyte-macrophage colony-stimulating factor (GM-CSF) upon IAV
infection, which is necessary for the recruitment of DCs and downstream adaptive immune
responses (125). This critical role in orchestrating the immune response to IAV also means
that dysfunctional alveolar macrophages have the potential to be highly pathogenic, as will
be discussed in later sections of this thesis.

1.4.2 Adaptive immune responses to IAV
Clearance of IAV infection usually relies on an effective adaptive immune response.
Optimal virus clearance is characterized by vigorous humoral and cell-mediated responses,
and the generation of memory cells specific for IAV can effectively prevent re-infection
by the same virus many years later.

1.4.2.1 Humoral responses
Infection with IAV results in production of IgG, IgM and IgA isotype antibodies.
Typically, the antibodies that confer protection against re-infection are of the IgG isotype
and are directed against the HA and NA proteins on the surface of IAV (126). The
prevention of re-infection is largely attributable to the neutralization of the virus mediated
by the binding of Ab to HA, and high serum titres of HA-specific IgG are an excellent
correlate of protection against infection with antigenically similar IAV strains (127). The
HA molecule on the surface of IAV exists as a trimer, with each subunit consisting of a
stalk region ending in a globular head (128). Binding of Ab to this head domain prevents
the HA molecule from binding to the sialic acid receptor on the surface of epithelial cells
in the respiratory tract, preventing virus entry into the cell. Abs against the stalk domain
are also formed, but these are subdominant to the head domain antibodies and do not
typically prevent viral entry unless the virus is present in very high titres (129). NA-specific
IgG antibodies are also present after IAV infection, though these likely do not protect
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against initial infection (130). The function of NA is to cleave sialic acid on the surface of
the host cell, allowing newly-formed viral particles to detach from the cell membrane. NAspecific Abs block this sialidase activity, thereby limiting the spread of the virus to
uninfected cells. Both HA and NA-specific Abs also have the capacity to initiate antibodydependent cell-mediated cytotoxicity (ADCC) by NK cells, which can further contribute
to virus clearance by removing IAV-infected cells (131). Ab responses against the M2 and
NP proteins have also been detected, though these tend to have low titres and constitute a
mode of protection that is incompletely understood (132, 133).
IgM antibodies are present during primary infection with IAV and almost entirely absent
during secondary infection due to B cell class-switching to other isotypes. IAV-specific
IgM can neutralize IAV by binding the viral particles and by activation of the complement
pathway (134). The presence of serum IgA seems to be indicative of recent IAV infection,
while IgA that is produced in the respiratory mucosa can confer local protection against
viral infection (135). While IgA and IgM can both confer some degree of protection against
IAV infection and morbidity, IgG is the crucial antibody isotype for control of both primary
and secondary infection (136).

1.4.2.2 Cell-mediated responses
The involvement of CD4+ T cells in IAV-specific immunity is largely to provide help to
macrophages and IAV-specific B cells. A balance must be achieved with regards to the
induction of Th2 versus the Th1 responses (production of IFNγ) that are necessary for the
formation of memory CD8+ T cells (137). The typical CD4+ T cell response to IAV is
predominantly Th1-skewed, though this has to be kept under tight control by T regulatory
(Treg) cells to prevent immunopathology (138, 139). The presence of long-lived CD4+
memory T cells in the lung has also been correlated with protection against IAV infection
(140). Evidence has also suggested a role for cytolytic CD4+ T cells in the IAV-infected
lungs as contributors to IAV-specific immunity, especially in the context of heterosubtypic
infection (141). T regulatory (Treg) cells also play a role in the control of immune
responses to IAV. They are necessary to prevent excessive inflammatory responses and
subsequent tissue damage during the response to IAV (139).
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TCD8+ are important for the control of primary infection with IAV (142). They are
recruited to the lungs after activation in the lymphoid tissues where their function is to
eliminate virus-infected cells. They typically do so via the perforin/granzyme pathway,
though gene knockout approaches have shown that CD8+ cytotoxic T cells can kill IAVinfected cells through other pathways if the perforin/granzyme pathway is unavailable
(143). TCD8+ can recognize epitopes derived from the internal proteins of IAV, which are
more likely to be conserved in comparison with exterior proteins that are subject to
selection pressure to avoid neutralization by Abs (144). However, the role of CD8+ T cellmediated protection in humans has been difficult to study due to the dominant role of Ab
responses in protection against IAV infection. Recent evidence from individuals infected
during the H1N1 pandemic showed that the presence of heterosubtypic CD8+ T cells was
correlated with lower lung viral titres (145). In addition, a study of severe H7N9 infection
cases requiring hospitalization showed that early heterosubtypic CD8+ T cell responses
were correlated with increased survival and earlier discharge from hospital (146).

1.4.3 Immune evasion mechanisms
As discussed earlier, antigenic drift and shift result in the evolution of viruses that avoid
neutralization by IAV-specific antibodies. In addition to changing its antigenic profile, IAV
has evolved numerous ways to evade and interfere with the host immune response despite
its relatively small complement of proteins (12 in total) (80). The IAV protein with the
most prominent role in control of the host immune response is non-structural protein 1
(NS1). This protein can interfere directly with innate immune sensors such as RIG-I and
protein kinase R (PKR), preventing them from performing their function as sensors of viral
RNA (147, 148). NS1 can also interfere with 3’ polyadenylation of host mRNA as well as
its export out of the nucleus, which reduces the capacity of the host cell to express antiviral
proteins (149, 150). In addition, the mere presence of replicating IAV within the host cell
creates competition for cellular resources, further hindering the ability of the cell to mount
an antiviral response. The viral RNA polymerase steals 5’ caps from processed host
mRNAs to attach to viral RNA destined for translation by the host ribosome, which
decreases the translation of host proteins (151). The PB1-F2 protein, in addition to its role
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in promoting cell death, has been shown to interact with IKKb to prevent nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) signalling (152).

1.4.4 Vaccination against influenza A virus
Though antiviral drugs such as the neuraminidase inhibitors oseltamivir and zanamivir
continue to be used to treat IAV infection, a more attractive strategy for the control of IAV
is through the use of vaccination. Neutralizing antibody responses are typically directed
against the globular head domain of the HA protein on the surface of IAV (128). This
interferes with the binding of HA to sialic acid receptors on the surface of the target cell,
preventing viral entry and infection. Both serum IgG and mucosal IgA responses have
proven efficacious in this capacity (136). Antibody responses directed against NA can also
limit the spread of IAV by preventing the nascent virus from leaving the host cell
membrane (130). Current seasonal IAV vaccines are formulated against the predominant
seasonal H3N2 strain, an H1N1 strain and one influenza B strain (153). They induce strong
antibody responses against HA, providing excellent protection if there is a good match
between the vaccine strains and the naturally circulating IAV. However, this strategy relies
on the accurate prediction of which flu strains will be circulating in the coming year, an
approach that is often imperfect given the potential for antigenic shift events to occur
without warning. To get around this problem there has been a great deal of interest in the
generation of IAV vaccines that produce antibody responses against the highly conserved
stalk domain of the HA protein (154). Stalk-specific antibodies are naturally present after
vaccination with whole, split-virion or HA-based vaccines, but they are subdominant to the
head antibodies (155). Therefore, only a precious little is known about their ability to
protect against IAV infection. Several groups are currently working on this problem, and
there have emerged several promising vaccine candidates that have been shown to confer
protection in mouse models of IAV infection (156, 157, 158, 159).
In addition to vaccines that rely on antibody-mediated protection, there exists potential for
the use of CD8+ T cell-based strategies in the context of therapeutic vaccination against
IAV. Though such a vaccine would be less useful in preventing infection (CD8+ T cells by
definition eliminate cells that are already infected), they could be very useful for the
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treatment of primary IAV infection. TCD8+ recognize epitopes derived from the interior
of the virus as well as the exterior, and thus could potentially eliminate viruses that have
escaped antibody-mediated neutralization (160). The interior proteins of IAV are also
subject to less intensive selection pressure than HA and NA, and are therefore more likely
to be highly conserved (161). This opens up the possibility of using CD8+ T cell vaccination
strategies to confer heterosubtypic immunity to current as well as future IAV infections.
One potential barrier to effective humoral and cellular vaccine strategies against IAV is the
phenomenon of “original antigenic sin” (OAS). This was first noticed in the context of
antibody responses to IAV, in that people who had been vaccinated against a given strain
of IAV only produced Abs against that particular strain, even after vaccination with highly
immunogenic epitopes from other viral variants (162, 163). OAS is thought to arise because
antibodies and CD8+ memory T cells that recognize the original virus mask any response
of naive adaptive cells specific for epitopes from the new virus (164). Vaccination with a
virus that shares no cross-reactive epitopes is one way to overcome OAS, though this is
not a realistic strategy for seasonal influenza given the potential for year-to-year antigenic
similarity between viruses. Other strategies to mitigate OAS include delivery of high
antigen loads and the inclusion of B cell adjuvants to boost responses to the new virus (165,
166) Any successful IAV vaccine will have to take the OAS into account, especially when
dealing with highly heterogeneous human populations.

1.5. Animal models of influenza A virus infection and
vaccination
Data on IAV-associated morbidity and immunity in humans is derived from cases of
natural infection with seasonal and pandemic IAV, as well as limited volunteer studies that
have utilized low doses of flu and attenuated strains (167, 168, 169, 170). For these reasons
a number of different animal models have been developed to study the course of IAV
infection as well as the efficacy of vaccination and other therapies to prevent and treat IAV
infections.

1.5.1 Mice
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Mice are far and away the most popular model for IAV, despite the fact that influenza is
not a natural mouse pathogen. There are many inbred strains, knockouts, and speciesspecific regents tailored to the study of IAV infection in this model. However, mice are not
susceptible to infection with human-adapted IAV strains, and even after infection they are
not typically capable of transmitting the virus to other mice by contact or by aerosol (171,
172). The airways of mice typically feature α2,3-sialic acid linkages, while human IAV
has adapted to recognize α2,6 linkages (173, 174). Therefore, the study of IAV in mice
typically relies on the use of mouse-adapted IAV strains such as A/Puerto Rico/8/1934
H1N1 (PR8), which are highly lethal in inbred laboratory strains due to the lack of a
functional Mx1 protein in these animals (175, 176).
In addition to differences in viral tropism, IAV infection in mice results in a different
constellation of symptoms than those observed in humans. Instead of developing fever,
IAV-infected mice are typically hypothermic and display a hunched posture, ruffled fur
and weight loss (177). They don’t develop sneezing or coughing, but examination of the
lung tissue of infected mice after euthanasia reveals tissue destruction as well as the
infiltration of macrophages and neutrophils (178). Despite the differences between humans
and mice in terms of viral tropism and pathology, mice remain a very useful model for
studying influenza due to the comparatively low cost of husbandry and wide availability
of reagents (177).

1.5.2 Ferrets
Ferrets are considered a good model for IAV infection because they are one of the few
animals that display human-like symptoms when infected with human-adapted IAV (179,
180). Infection by IAV in ferrets manifests as an upper respiratory tract infection,
accompanied by sneezing, fever, nasal congestion, weight loss and lethargy (180).
However, a notable difference between the course of disease in ferrets as compared to
humans is the tendency of some virus strains, notably highly pathogenic Asian influenza
(HPAI) and H5N1, to infiltrate the central nervous system and cause virus-induced
encephalitis (181). In addition to being naturally susceptible to infection with human IAV,
they can also be infected with influenza viruses originating from birds and swine (182,
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183). Transmission of infection between ferrets also closely parallels what is observed in
human populations, as IAV can be spread between animals by direct contact and aerosols
(184). This makes ferrets a suitable model for IAV transmission as well as pathogenesis.
The main drawback associated with studying IAV infection using a ferret model is the cost.
Ferrets are larger than mice and thus require more space for housing (177). In addition, the
specialized nature of the ferret model has resulted in a relative dearth of reagents, such as
specific monoclonal antibodies, when compared to more commonly used animal models
such as mice. The availability of inbred and genetically engineered strains is also limited
when compared to the options available for rodent models. Nevertheless, the close
similarities between the course of disease in ferrets and humans make these animals an
excellent choice for studies of IAV transmission and pathogenesis.

1.5.3 Guinea pigs
Guinea pigs are also able to be naturally infected with human-adapted strains of IAV,
though viral titres in the lungs and airways tend to be lower than those found in humans
and ferrets (172). It is also possible for the virus to be transmitted between animals via
direct contact or aerosol (185). Guinea pigs are also easier and less expensive to house than
ferrets, though the model still suffers from a relative lack of commercial species-specific
reagents. The main drawback of the guinea pig model is the lack of symptoms associated
with IAV infection (186, 187). The dose of IAV needed to cause mortality in guinea pigs
in much higher than that in the ferret model, and the overt signs of disease are confined to
very limited weight loss, nasal mucus production and listlessness, even for highly
pathogenic IAV strains (187). However, histopathological changes as a result of infection
can be observed in the lungs, as well as immune cell infiltration (187). The lung
architecture of guinea pigs is also more similar to humans than other animal models (188).

1.5.4 Nonhuman primates
The obvious attraction of a nonhuman primate (NHP) model is the relatively close genetic
and physical similarities between NHPs and humans. Macaques are the preferred NHP
model for influenza studies, largely because of their smaller size and less extensive housing
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requirements as compared to other primates such as chimpanzees (177). NHPs can be
infected with unadapted human strains of IAV, resulting in similar morbidity and viral
titres (189, 190, 191). Animals that are infected with IAV display the typical symptoms of
viral pneumonia in humans, such as fever, cough, and lethargy (189). In cases where
macaques were euthanized after infection high viral titres were found in the lungs, as well
as pathology typical of IAV pneumonia in humans (189, 192). However, IAV studies using
NHPs tend to be rare due to the cost and ethical concerns surrounding research using these
animals.

1.6. CD8+ T cell responses to influenza A virus
Though the study of long-term immunity to IAV is mostly focussed on the generation of
memory B cells and enhancement of neutralizing antibody responses, TCD8+ remain an
important cell type in anti-influenza immunity. Their activation and effector activities are
important for the primary response to novel IAV strains, against which neutralizing
antibodies have not had the time to form. TCD8+ also recognize epitopes derived from the
highly conserved interior of the virus, making them an attractive therapeutic target for the
control of heterosubtypic infections.

1.6.1 Naive IAV-specific CD8+ T cells
IAV infection begins when the cells of the upper respiratory tract come into contact with
virus delivered on airborne droplets. The infection is usually confined to this area but can
spread to the lower respiratory tract and lungs, resulting in a more severe disease (192).
Naive TCD8+ that are specific for IAV reside in the secondary lymphoid organs such as
the spleen and lymph node after exit from the thymus. They remain in these tissues and in
the circulation until activation by DCs displaying IAV-derived peptide epitopes. Human
studies of natural infections have demonstrated that the number of naive IAV-specific T
cells is negatively correlated with symptom severity (145). In addition, early and robust
TCD8+ responses ostensibly enabled by higher numbers of IAV-specific CD8+ cytotoxic
T lymphocyte (CTL) precursors were associated with decreased morbidity and mortality
after primary H7N9 infection (193).
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1.6.2 Phases of the TCD8+ response to IAV
CD8+ T cells are part of the adaptive arm of immunity, and thus require a few days in order
to become fully activated and able to traffic to the site of infection in response to
inflammatory signals (194). Once in the lungs effector TCD8+ quickly search out IAVinfected cells and destroy them, before undergoing deletion. At the same time, memory
cells specific for IAV epitopes are generated. Memory precursor cells that do not express
the interleukin-7 receptor (IL-7R) undergo cell death, while IL-7R+ cells survive to form a
pool of long-lived memory cells (195). These memory cells are then available for reactivation upon re-infection years after the initial event, whereupon they rapidly proliferate
and differentiate into a new batch of effectors. Each phase of this process is covered in
more detail in the following sections.

1.6.2.1 Priming of naive TCD8+
Antigen presentation to naive T cells in the lymph nodes draining the lung is largely
mediated by DCs. In the infected lung, DCs can acquire IAV-derived antigen through
cross-presentation pathways after phagocytosis of dead or dying lung epithelial cells. In
addition, there is also some degree of antigen transfer between migratory DCs from the
lung to resident lymph node DCs, which then present the Ag to naive TCD8+ (196).
Infection of lung migratory DCs directly by IAV does not often occur, as they typically are
protected by increased type I IFN signalling activity (197). Upon antigen acquisition the
mature DC up-regulates CCR7 expression on their surface, which allows them to travel to
the lymph node (198). This wave of DC antigen capture and migration from the lung to the
LN takes place in the first 4 days after IAV infection (198). In mouse models, deletion of
CD103+ DCs, the subset that plays the greatest role in cross-priming during IAV infection,
causes delayed primary TCD8+ responses and viral clearance (199). In mice, the vast
majority of naive T cell priming occurs in the draining regional lymph nodes, with a smaller
population undergoing priming in the spleen (200). The activation of a naive T cell requires
three signals: Recognition of the peptide/MHC complex through the TCR, costimulation
through CD28 by CD80/86 on the APC, and release of appropriate cytokines such as IL-2
(20363604). If any one of these signals is missing the naive TCD8+ will likely die of
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apoptosis or become anergic to any further TCR signalling. During this priming step
TCD4+ cell help is needed for generating optimal TCD8+ memory responses, but is not
essential for the primary response (201, 202). The naive T cells quickly proliferate,
expanding in number at least 10-fold before starting to migrate out of the lymph node to
other sites by day 5 after infection by selective loss of CD62L (203).
Once activated, the CD8+ T cells exit the lymph node and travel to the lung. This is
achieved primarily through the expression of CD11a on the CD8+ T cells, which bind the
ligand intercellular adhesion molecule-1 (ICAM-1) on the surface of the lung epithelial
cells (204). This allows CD8+ T cells that have entered the circulation to be recruited
specifically to the lung tissue, with additional roles being played by LFA-1 expression and
CCR4 expression on the T cells themselves (204, 205). Entry into the airway from the
circulation is achieved in response to IL-15, which in itself is an inducer of CD11a
expression (206). IL-15 expression is induced by type I IFN production, thus helping the
circulating CD8+ T cells to end up in the right location (207).

1.6.2.2 TCD8+ effector function
The main function of an activated, antigen-specific TCD8+ is to kill host cells displaying
their cognate peptide antigen in the context of MHC I. This signals to the TCD8 + that the
host cell has become infected by a virus and as such it needs to be eliminated to prevent
propagating the infection. TCD8+ can kill their targets using one of three (technically four)
ways. The most prominent pathway used by TCD8+ in response to detection of an IAVinfected cell is the perforin/granzyme pathway, in which perforin molecules produced by
the CD8+ T cells get inserted into the membrane of the target cell, forming a pore on its
surface (143). The CD8+ T cell then releases granzymes through the pore and into the
target cell, resulting in the activation of intracellular caspases and the induction of
apoptosis. CD8+ T cells also express Fas ligand (FasL) on their surface, which can bind
Fas on the infected target cell to induce apoptosis (208, 209). The third killing mechanism,
expression of TRAIL and its engagement with TRAIL-DR on the target cell surface, works
on a similar principle. Both induce intracellular signalling that converge on the caspase
pathway to induce the formation of an apoptosome and subsequently induce cell death
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(210). Effector CD8+ T cells are major producers of IFNγ and TNFα, both of which
contribute to anti-IAV responses (209). IFNγ, in addition to its stimulatory effect on other
TCD8+, also enhances the class-switching of B cells (211). TNFα production is technically
the fourth method of killing by activated TCD8+, but it is non-specific and doesn’t typically
require cell-to-cell contact to exert its effects (212). Binding of TNFα to the TNF receptor
on the target cell surface will induce apoptosis, though excessive TNFα production is
associated with immunopathology (213). Effector TCD8+ responding to IAV infection
show great flexibility in their choice of pathway when lysing target cells. Mouse studies
have shown that genetic knockout of the granzyme A/B pathway does not lead to increased
morbidity as a result of IAV infection in a mouse model (214). The same effect was
observed for the genetic ablation of killing by the Fas/FasL pathway, however knockout of
both at the same time resulted in a lethal infection (143). Another group has shown that
interfering with the TRAIL pathway for killing resulted in greater morbidity and higher
viral loads (215). Effector CD8+ T cells that can produce more than one cytokine at a time,
namely IL-2, IFNγ and TNFα, are generally more protective than cells that produce only
one or two of the cytokines (216).

1.6.2.3 Recall and memory responses to IAV
Successful resolution of the primary infection results in the contraction of the CD8+ effector
T cell population and generation of a long-lived pool of IAV-specific memory TCD8+.
However, the longevity of IAV-specific memory cells in humans is unclear. One study
tracking the cytotoxic potential of IAV-specific TCD8+ showed that by 5 years the ability
of these cells to kill their target in an ex vivo
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Cr- release assay was diminished (217).

However, other studies merely looking for the presence of memory IAV-specific TCD8+
by tetramer staining could locate them for as long as 13 years after initial infection (218).
Indeed, cases of natural infection with the 2009 H1N1 viruses showed that older adults
who had pre-existing cross-specific immunity from earlier flu infections had lower
symptom scores than those who did not have cross-reactive TCD8+ (145).
In response to IAV infection in the lungs, memory TCD8+ that reside predominantly within
the lung tissue and draining lymph nodes are re-activated (219). The number of memory
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cells for a given antigen is markedly higher than the number of naive CD8+ T cells that
had existed before antigen contact, so this expansion happens much more quickly than the
expansion of naive CD8+ T cells (220, 221). The population of cells that makes up the
memory CD8+ T cell compartment is heterogeneous; it can be roughly divided into central
memory and effector memory subsets. Central memory cells express CD127, CD45RO and
CCR7, with CCR7 expression acting to keep them in the lymph node (222 ). This second
category, the effector memory CD8+ T cells, express CCR3 and CCR5 that allow them to
respond to inflammatory signals in the lung tissue. Once the effector memory cells are
activated they proliferate and give rise to effector CD8+ T cells, which then seek out and
lyse target cells displaying their cognate antigen. In terms of viral clearance memory CD8+
T cell responses are dispensable given the presence of neutralizing Ab responses, but in
the case of incomplete or absent neutralization, they can reduce symptom severity and
provide some degree of heterosubtypic protection (126, 223).

1.6.3 Immunodominance in CD8+ T cell responses to IAV
Immunodominance (ID) describes the propensity of T cell responses to be directed against
only one or few peptides rather than being distributed evenly amongst the multiplicity of
different epitopes that could be recognized from a given pathogen. The reasons for the
formation of ID hierarchies, and why some epitopes produce measurable T cell responses
while others fail to do so vary depending on the system being investigated. In the case of
human IAV infection in HLA-A2+ individuals, the vast majority of TCD8+ responding to
infection are directed against M158-66 (224). In addition, almost all M158-specific TCD8+
have a Vβ17+ TCR across most individuals studied (225). Structural analyses have shown
this is due to this particular TCR makeup being very good at binding M1 point mutants
with relatively high affinity, meaning that M1 can mutate without losing the ability to bind
M158 (226). In addition, upon TCR binding, the M1 peptide is squeezed into a relatively
flat conformation that is easily recognizable by the Vβ17+ TCR regardless of point
mutations (227). For the IAV-specific TCD8+ response in mice, ID hierarchies arise due to
the relative abundance of proteins from which dominant peptides are derived (as is the case
with NP) and due to the avidity with which some peptides bind MHC and TCR. This is the
case with the co-dominant NP336-374 response in B6 mice, as the NP336 peptide is able to
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bind its cognate TCR with high avidity, out-competing other T cell clones despite similar
precursor numbers. Immunodominant responses are not always immunoprotective, as these
responses are under stronger selection pressure and thus may be more susceptible to
mutation (228, 229). In this case it is desirable to design therapies that can boost
subdominant responses in order to deal with possible escape mutants within a viral
population.

1.7 Coinfection with IAV and Gram-positive bacteria
Clinically, opportunistic bacterial infections in the IAV-infected lung are a significant
problem. Pulmonary complications subsequent to IAV infection have been noted as far
back as the 1918 Spanish Flu pandemic, and Gram-positive bacteria such as S. pneumoniae
and S.aureus continue to be major complicating pathogens in secondary bacterial
pneumonias (230). As well, coinfections between Gram-positive bacteria and IAV have
the opportunity to occur during the immunosuppressive phase of recovery after TSS (231)
or microbial sepsis (232, 233).

1.7.1 IAV infection of septic and toxic shock patients
It has previously been noted in the medical literature that survivors of sepsis and TSS have
an elevated risk of dying from non-septic illnesses that lasts for years after recovery (234,
235). In addition, patients recovering from sepsis have an increased susceptibility to
secondary infection and increased odds of latent viral reactivation, both of which can prove
deadly (236). The mechanism underlying this increased susceptibility to illness and death
has been a subject of investigation using many different models of sepsis followed by
infection. Badovinac et. al. have observed that mice with sepsis induced by cecal ligation
and puncture (CLP) that were allowed to recover had an altered TCD8+ repertoire that
lasted for months after recovery from sepsis (237). More specifically, they found naive
TCD8+ that were specific for lymphocytic choriomeningitis virus (LCMV) were reduced
in number after recovery from CLP. The relative dearth of naive precursors in the postCLP mice resulted in a smaller TCD8+ response to subsequent LCMV infection. The same
group in a follow-up study also noted that TCD8+ that were capable of responding to
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infection were more easily exhausted (as determined by expression of exhaustion markers
and reduced cytokine expression by Ag-specific T cells) than cells from mice that had not
been subjected to CLP (238). Human studies addressing the same problem have revealed
that T cells in septic patients down-regulate pro-survival factors such as Bcl-2 and display
increased apoptosis (239, 240). Epidemiological studies have also shown that sepsis
survivors are much more likely than the average population to die from infectious illnesses
caused by a variety of bacteria, fungi and viruses (241). Though data regarding the cooccurrence of IAV infection and TSS is more difficult to find (likely due to the rarity of
TSS), cases have been reported in which bacterial TSS is noted as a complication of IAV
infection (242, 243). In both of these cases bacterial colonization of the respiratory tract
during IAV infection acted as the trigger for TSS. Another report shows this happening on
a larger scale, with the outbreak of IAV among patients in a psychiatric facility being
complicated by concomitant bacterial TSS (244).

1.7.2 Secondary bacterial pneumonia complicating IAV
infection
Secondary bacterial pneumonia is a well-known complication of IAV infection with a long
clinical history. During the 1918 Spanish flu pandemic up to 95% of all deaths had some
bacterial involvement, typically S. pneumoniae (245). This pattern was repeated during the
1957 and 1968 flu pandemics, where autopsies revealed that close to 75% of those who
died had a form of bacterial pneumonia, though by this time the bacteria that were
predominantly found consisted of P. aeruginosa and S. aureus (246, 247). In the latest flu
pandemic, the 2009 H1N1 swine flu outbreak, roughly 30% of all fatal cases had bacterial
involvement despite increased usage of antibiotics. Most cases of bacterial coinfection
were due to S. pneumoniae, S. pyogenes or S. aureus depending on geographical location
(248, 249).
There are many ways in which IAV and bacteria in the infected lungs can act
synergistically to enhance infection and replication. The most obvious way is through the
direct damage IAV inflicts upon the respiratory epithelium, which liberates nutrients and
creates more surface area for bacterial attachment (250). This direct damage can be
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augmented by the expression of especially virulent variants of the PB1-F2 protein, which
causes increased cytotoxicity relative to the wildtype protein (251). This has been shown
experimentally in mice; a study by Iverson et. al. using superinfection with S. aureus after
IAV infection showed that mice infected with PB1-F2 deletion strains had less mortality
than those infected with WT virus (252). In addition, damage caused by IAV infection can
result in the destruction of ciliated airway cells, which hampers the ability of the airway to
mechanically remove debris and bacteria (253). The NA activity of IAV after viral exit can
also cause the exposure of novel binding sites for bacteria by cleaving sialic acid from the
cell surface (254). Changes in the activation state of epithelial cells in response to
inflammation can also cause the expression of different cell surface proteins that bacteria
can use as sites of attachment (255). A more subtle form of synergy between bacteria and
IAV occurs due to the fact that immune skewing towards an antiviral response hinders any
concomitant action against invading bacteria (256). Efficient clearance of bacteria from the
lungs requires a Th17 response, which is characterized by production of IL-17 by TCD4+
and is inhibited by type I IFN signalling induced by IAV infection (257). Repression of
this response results in reduced TLR ligand signalling and subsequent poor recruitment of
neutrophils to the lung in response to bacterial infection (258). IAV infection also causes
alveolar macrophages to down-regulate the expression of macrophage receptor with
collagenous structure (MARCO), a key scavenger receptor necessary for the innate
recognition of bacterial infection (259, 260).

1.7.3 Superantigens and IAV
The likelihood of IAV infection being complicated by concomitant bacterial invasion (and
vice versa) raises the question of why these coinfections occur with such frequency.
Bacterial species such as S. aureus and S. pyogenes both encode SAgs that have significant
effects on immune cells (261). Bacterial superantigens are noted for their ability to induce
proliferation of both CD4+ and CD8+ T cells bearing certain Vβ regions as a part of their
TCR, which is thought to be followed by deletion or anergy of the responding T cells. The
CD8+ T cell responses directed against immunodominant IAV epitopes in both BALB/c
mice and in HLA-A2+ humans utilize Vβ regions that are known to bind certain SAgs (262,
263). It stands to reason that bacterial SAgs may hinder the T cell-mediated response to
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IAV causing the deletion or anergy of T cell clones that are needed for effective adaptive
immunity to IAV.
The evidence supporting the idea that SAg administration results in proliferation followed
by anergy or death largely stems from experiments using in vivo administration of SEB
followed by in vitro restimulation of T cells. These observations consisted of a lack of IL2 production and Vβ8+ T cell proliferation following the in vitro re-exposure to the same
SAg (54, 264). This lack of proliferation could not be rescued by exogenous addition of
IL-2, and was found to persist for at least a month after contact with SEB. In addition to
inducing anergy in bulk primary T cells, antigen-specific memory T cells were found to
display an anergic phenotype after SEB administration. In one paper, mice with memory
cells specific for the model antigen keyhole limpet hemocyanin (KLH) were treated with
SEB and the ability of these CD4+ cells to provide help to B cells for antibody production
was assessed (265). When cultured with B cells, the memory CD4+ T cells from SEBtreated mice were less able to stimulate KLH-specific Ab production. Another group later
reported a similar CD4+ T cell response to SEB in mice transgenic for an ovalbumin
(OVA)-specific Vβ8.2+ TCR (266). Notably, the bulk of the literature concerning T cell
anergy in response to SEB has focussed on CD4+ T cell responses rather than CD8+ T cells.
Previous studies examined the effect of SEB on cell-mediated responses to IAV. In 1996,
Zhang et. al. (267) noted that administration of sub-lethal amounts of SEB to mice infected
with a sub-lethal dose of IAV induced mortality that was dependent on the relative timing
of infection and SEB administration. Maximum mortality occurred when the mice were
given SEB 7 days after IAV infection, which corresponds to the peak of the primary CD8+
T cell response to IAV. They further noted that this mortality was dependent on the
presence of SEB-reactive T cells; mice that had their Vβ8+ T cell population experimentally
depleted on day 5 after infection (2 days before SEB administration) were significantly less
likely to die than control mice. The enhanced mortality was linked to the production of
TNFα and IFNγ; administration of these cytokines in place of SEB partially recapitulated
the observed phenotype. Four years later, the same lab published a study examining the
effect of SEB and the related SAg SEA on the primary and recall responses to IAV
infection (268), expanding on the findings reported in the previous paper. Their
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experiments utilized B6 mice, whose CD8+ T cell response to IAV is characterized by the
co-dominance of NP366- and PA224-specific CD8+ T cells. Detection of NP366-specific cells
in the bronchoalveolar lavage (BAL) fluid and other tissues was accomplished using an
MHC I tetramer. These NP366-specific CD8+ T cells are known to be Vβ8.3+, which are
sensitive to SEB but not to SEA (269). On day 7 after intranasal IAV infection the mice
were given an intraperitoneal injection of SEB, resulting in the expansion of NP366-specific
cells in the peripheral blood and BAL. The number of these cells had returned to baseline
by 8 days after SEB administration. Neither SEB nor SEA caused a change in the
percentage of NP366-specific cells, though cytotoxic killing of IAV-infected target cells as
measured by 51Cr-release assay was elevated for cells recovered from the BAL for both
SAgs up to two days after injection. Curiously, viral clearance from the airways for both
SEA- and SEB-treated mice was delayed as compared to mice injected with vehicle. In
addition, there appeared to be no effect of SEB injected during the primary response on the
secondary response to intranasal IAV challenge as measured by the relative expansion of
Vβ8.3+ NP366-specific cells.
Subsequent papers examined the effect of SEB in memory responses to IAV. In particular,
a 1997 paper by Coppola et. al. reported that far from inducing anergy, SEB actually
reactivated IAV-specific CD8+ T cells (270). The authors used a model that involved
intranasal infection of CBA/CaJ mice as well as mice on the same background bearing a
TCR transgene for Vβ8.1. The mice were given time to recover from the infection and
develop a stable memory repertoire, at which point the mice were injected with SEB i.p.
and had their splenocytes harvested. Using a chromium release assay utilizing L929 cells
infected with IAV, they found that CD8+ T cell-enriched samples induced massive IAVspecific killing after in vivo or in vitro SEB stimulation. They further showed that this
killing was partially TCR-dependent as the mice bearing the SEB-reactive transgenic TCR
had greater specific killing at comparable effector:target ratios. Though not directly shown,
the authors also asserted that the IAV-specific effector CD8+ T cells proliferate and secrete
IL-2. However, a later paper published by the same lab highlighted a different interaction
between SAgs and IAV-specific memory CD8+ T cells (271). In this paper, the authors
used B6 mice that had been intranasally infected with IAV, as the immunodominant NP366specific response is known to mainly consist of cells bearing Vβ8.3+ TCRs in this strain.
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SEB was administered subcutaneously via an implanted pump, which gradually released
small amounts of SEB over the course of 7 days. They then used NP366-specific tetramer
to assess the frequency of epitope-specific cells in the BAL fluid after secondary exposure
to IAV. They found that Vβ8.3+ NP366- specific cells were decreased in the SEB-treated
mice, and that bulk BAL cells from the SEB-treated mice were less effective at lysing
NP366-pulsed L929 target cells. Assessment of viral titres in PBS- versus SEB-treated mice
after secondary infection showed no defect in clearance in the SEB-treated mice, though
experiments with thymectomized animals showed that naive T cells from the thymus were
responsible for compensating for the defective memory response.
Overall, the literature paints a picture of influenza-specific TCD4+ anergy induced by SEB,
with the effect of SEB on the TCD8+ response being less clear (Fig. 1). Most studies that
touch on the effect of SAgs on TCD8+ utilize a two-hit model of SAg administration rather
than following the effect of one exposure to SAg, or focus on bulk polyclonal TCD8+
reponses. Interpretation of the biological role of SAg on antigen-specific TCD8+ responses
is further complicated by examination of only the TCD8+ population specific for the
immunodominant peptide in a given response. In addition, Ag-specific TCD8+ populations
are examined using MHC I tetramer reagents, which fail to detect cells that have
internalized their TCR due to activation.

36

Figure 1. Schematic representation of the “hole in the repertoire” posited to exist after
SAg exposure. SAg-reactive cells are shown in dark grey, whereas T cell clones that do
not bind SAg are represented in light grey.
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1.8 Rationale and hypothesis
Previous investigations suggest that SAg administration can cause the deletion or
functional inactivation of cells in the T cell compartment (54, 264, 271). The human and
mouse response to IAV is known to contain T cell populations for immunodominant
antigens that bear SAg-reactive Vβ regions (262, 263). However, surprisingly little work
has been done to investigate how SAgs affect antiviral T cell responses. Most work to date
has focussed on CD4+ T cell responses to IAV in the context of active IAV infection, which
can make it difficult to dissect out the mechanisms underlying any observed changes in the
immune response (265, 266). In addition, the effect of SAgs on antigen-specific TCD8+
has not been comprehensively examined. Therefore, I hypothesize that bacterial SAgs will
alter the magnitude and/or breadth of the CD8+ T cell responses to IAV.

1.9 Specific aims
i. Characterize how exposure to bacterial SAgs affects the magnitude and the breadth of
primary, recall and memory TCD8+ responses to IAV in a mouse model.
ii. Determine the mechanism behind the immunodominance changes observed in aim i,
with specific attention to how this mechanism differs depending on the phase of the IAVspecific immune response.
iii. Evaluate the effect of bacterial SAgs on the functional capacity and fate of epitopespecific TCD8+.
iv. Determine the effect of bacterial SAgs on human virus-specific memory TCD8+, and
whether the mechanisms behind these changes are the same as in the mouse model.
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Chapter 2: Materials and Methods
2.1 Ethics
All animal experiments and husbandry was carried out according to the guidelines set out
by the Canadian Council on Animal Care (CCAC) under protocols (AUP #2010-241 and
AUP #2018-093) approved by the Animal Use Subcommittee at Western University.
Human blood was collected from healthy donors that had provided written informed
consent under a protocol (HSREB #5545) that had been approved by the Western
University Research Ethics Board for Health Sciences Research Involving Human
Subjects. Our inclusion criteria consisted of healthy volunteers between 18 and 100 years
of age who were able to give free and informed consent. Donors were excluded if they fell
outside of the age range, were pregnant or if they had a psychiatric illness.

2.2 Mice
Female BALB/c mice between 8 and 16 weeks of age were purchased from Charles River
Canada (St. Constant, QC) and housed in the animal facility at the University of Western
Ontario. These mice were housed and treated according to the guidelines set out by the
Canadian Council on Animal Care.

2.3 Cell culture
Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s modified Eagle
media (DMEM) plus 10% fetal calf serum (FCS). The J774 mouse macrophage cell line
was kindly given by Dr. Bryan Heit (Western University) and maintained in DMEM plus
10% FCS. The T2 human lymphoblast cell line was received from Dr. Tania Watts
(University of Toronto) and cultured in complete Roswell Park memorial institute (cRPMI)
media. This media consisted of 10% FCS, 2 mM Gluta-MAX-I, 0.1 mM MEM nonessential amino acids, 1 mM sodium pyruvate, 10 mM HEPES buffer, 100 μg/mL
streptomycin and 100 U/mL penicillin. All cultures were kept at 37ºC in a humidified tissue
culture incubator plus 6% CO2.
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2.4 Preparation and injection of SAg
Recombinant SEB and SEA produced in Escherichia coli BL21 was purified by the
McCormick lab at Western University as detailed elsewhere (1, 2). For all experiments
involving SEB, BALB/c mice were given 50 μg of SEB in 200 μL of phosphate buffered
saline (PBS) by intraperitoneal (i.p.) injection. A mutant version of SEB that has attenuated
binding to the T cell receptor (SEBN23A) was also used in one experiment as a negative
control for T cell receptor involvement. Mycoplasma arthritidis mitogen (MAM) was
kindly provided by Dr. Hong-Hua Mu of the University of Utah. MAM was purified and
prepared as detailed in previous publications (3, 4). Briefly, M. arthritidis was grown to
senescent phase in autoclaved modified Edward-Hayflick medium, after which the whole
culture was subjected to (NH4)2SO4 fractionation. This was followed by sequential rounds
of gel filtration and cation-exchange chromatography prior to the final purification on a
fast protein liquid chromatography (FPLC) column. The in vivo dose for the mouse
experiments was 50 ng per mouse in 200 μL PBS+0.2% bovine serum albumin (BSA),
delivered by intraperitoneal (i.p.) injection.

2.5 Preparation and administration of IAV
Influenza A virus (IAV) was propagated by inoculation from a stock IAV solution into the
allantoic cavity of 10-day-old embryonated chicken eggs. Allantoic fluid was harvested
and pooled to create a new stock solution used for all subsequent experiments. Six different
IAV strains were used, with A/Puerto Rico/8/1934 H1N1 (PR8) being used for most
experiments. For other experiments, the strains A/Northern Territory/60/1968 H3N2
(NT60) (5), A/Hong Kong/01/1968 H3N2 (HK) (5), J1 (a strain with hemagglutinin (HA)
from HK and a PR8-derived core) (6), X31 (H3N2) (7) and sequential 12 (SEQ.12), a strain
that was generated by serial passage of PR8 in the presence of neutralizing antibodies
directed against HA (8). The SEQ.12 strain of IAV has internal epitopes that are identical
to IAV (PR8) though the external epitopes have been altered by sequential passage in the
presence of neutralizing antibodies. Mice received an i.p. injection of the infectious
allantoic fluid to expose their immune system to IAV without inducing the morbidity and
mortality associated with intranasal IAV infection. The allantoic fluid was diluted 1:1 with
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sterile PBS before injection of 500 μL (~600 hemagglutinating units) into the peritoneal
cavity. Measurement of the primary TCD8+ response to IAV was carried out on day 7 after
IAV injection, save for one experiment where SEB was given on day 7 and the TCD8+ cell
response to IAV was measured on day 10.
Measurement of the recall response to IAV was done in the context of a prime-boost i.p.
vaccination regime. The mice were given a priming i.p. dose of IAV (PR8) on day 0,
followed by a boosting dose of IAV (SEQ.12) on day 30 (9, 10). This strain must be used
for the boosting dose (as opposed to PR8) to avoid a neutralizing antibody response in vivo.
The magnitude and breadth of the TCD8+ response was measured on day 37 by intracellular
cytokine staining (ICS) IFNγ. The memory response to IAV was measured at least eight
weeks after i.p. IAV administration.
For the intranasal infection model, mice were given an intranasal dose of IAV (PR8)
corresponding to 0.3 50% mouse lethal dose (MLD50). The objective was to induce
morbidity without inducing mortality so that the TCD8+ cell responses can be measured on
day 10 after infection. To administer the intranasal dose, the mice were briefly anesthetized
using 20% (v/v) isoflurane (Baxter International) in a bell jar. Once the mice were
unconscious 25 μL total of the virus solution was delivered dropwise into the nares of the
mice at 12.5 μL per nare. The mice were briefly returned to the bell jar between a series of
drops to ensure that they remained deeply anesthetized; conscious mice are prone to
coughing that would prevent the solution from getting to the lungs. After infection, the
mice were monitored for morbidity (lethargy, piloerection, etc.) as well as weight loss. Any
mouse that lost 15% or more of their body weight was euthanized via cervical dislocation.

2.6 Preparation and administration of rVV
For the experiments involving recombinant vaccinia viruses (rVV), TCD8+ responses were
measured on day 7 after i.p. virus injection. The viruses used were two rVV strains
encoding NP147 (rVV-NP147) and HA518 (rVV-HA518) (from Dr. Jonathan Yewdell and Dr.
Jack Bennink, National Institutes of Health (NIH)) expressed as ER targeted minigenes to
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increase expression. The injection consisted of 5 million plaque forming units (pfu)
delivered i.p. in 200 uL PBS.

2.7 Intracellular cytokine staining
In all cases, splenocytes were collected from each mouse, as well as peritoneal exudate
cells (PECS) collected by peritoneal lavage with 1x PBS. To ensure an adequate number
of cells were available for staining, PECS from mice within each treatment group were
pooled together in the same tube. Both types of sample were treated with ammoniumchloride-potassium (ACK) lysis buffer to remove erythrocytes before enumeration using a
hemacytometer. For the intranasal model, BAL and lung cells were also collected. After
sacrifice, BAL was collected via lavage with 1 mL of 1x PBS, repeated 3 times in order to
collect the maximum number of cells. The lungs were then perfused with 1x PBS to remove
contaminating peripheral blood mononuclear cells (PBMCs) and then homogenized using
a glass homogenizer.
The cells to be used for staining were then transferred to 96-well plates and stimulated in
vitro with 500 nM of IAV-derived H2-Kd restricted peptides dissolved in 10%
dimethylsulphoxide (DMSO). These peptides were kindly provided by Dr. Jack Bennink
and Dr. Jonathan Yewdell of the National Institutes of Health, and were determined to be
>95% pure by high-performance liquid chromatography (HPLC). Each peptide solution
was stored at -30ºC in DMSO before dilution for in vitro usage. As a positive control,
400,000 J774 cells pulsed with IAV (PR8) were also included. After 2 hours of incubation
at 37ºC in a 6% CO2 incubator, brefeldin A (BFA) (Sigma-Aldrich) was added to all wells
at a concentration of 0.1 mg/mL to stop cytokine export. The plate was then returned to the
incubator for 3 additional hours before pelleting the cells by centrifugation and adding Fc
block (clone 2.4G2 from hybridoma supernatant) for 20 minutes at 4ºC. All cells were then
surface stained for 30 minutes in ice with anti CD8-APC (clone 53-6.7, eBioscience) before
fixation with 1% paraformaldehyde (Electron Microscopy Sciences). The cells were then
stained with anti-IFNγ-FITC (clone XMG1.2, eBioscience) while simultaneously being
permeabilized with 0.1% saponin overnight. The next day, the cells were washed and
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resuspended in FACS buffer (1x PBS + 0.5% BSA) before reading via flow cytometry on
a BD FACS Canto II flow cytometer.

2.8 Surface staining
Detection of specific Vβ region expression on bulk CD8+ T cells was accomplished using
the Mouse Vβ TCR Screening Panel produced by BD Pharmingen. A female, 8-week old
BALB/c mouse was sacrificed to procure a spleen, which was then mechanically
homogenized and treated with erythrocyte lysis buffer. The splenocytes were then split into
two equal portions and suspended in cRPMI +10% fetal calf serum (FCS) at a
concentration of 2 million cells/mL. This was followed by stimulation with 500 ng/mL
SEB or PBS and incubation for 3 days in a 6% CO2 incubator at 37ºC. The cells from each
condition were then stained with anti-mouse CD8α-Alexa Fluor 647 (clone 53-6.7,
eBioscience) and one of the FITC-conjugated anti-Vβ antibodies in the screening panel
before analysis via flow cytometry.
To detect the type of Vβ region possessed by IAV epitope-specific TCD8+ from mice
treated with SEB or PBS before i.p. IAV vaccination, the aforementioned surface and
intracellular staining protocols were used with a few modifications. Detection of
intracellular IFNγ was accomplished using an antibody conjugated to PerCP-Cy5.5 (clone
XMG1.2, eBioscience) rather than FITC. Staining of mouse Vβ regions was accomplished
using the Mouse Vβ TCR Screening Panel produced by BD Pharmingen.
For experiments in which cells were stained to determine the expression of fate-related
markers, the following antibodies were used: Anti-mouse CD3e-APC (clone 145-2C11,
BD Pharmingen), Anti-mouse Killer Cell Lectin Like Receptor G1 (KLRG1)-PerCPeFluor® 710 (clone 2F1, eBioscience), Anti-mouse/rat Bcl-2 PE-Cyanine7 (clone 10C4,
eBioscience), Anti-mouse CD279 (Programmed Death-1 (PD-1)) APC-eFluor® 780
(clone J43, eBioscience), Anti-mouse CD8α-Alexa Fluor 700 (clone 53-6.7, eBioscience),
Anti-mouse CD127-PE (clone A7R34, eBioscience) and anti-mouse IFNγ-FITC (clone
XMG1.2, eBioscience), Anti-mouse lymphocyte-activation gene 3 (LAG3)-PE-Cy7 (clone
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C9B7W, eBioscience). Surface and intracellular (in the case of Bcl-2) staining was carried
out as previously described in sections 2.7 and 2.8.

2.9 Tetramer staining of mouse TCD8
Two Alexa Fluor 488-conjugated tetramers were obtained from the NIH tetramer facility
and used to detect epitope-specific CD8+ T cells. These were specific for T cells
recognizing the H2-Kd restricted peptides TYQRTRALV and IYSTVASSL, corresponding
to NP147 and HA518 respectively (11, 12). The tetramers were used for staining at a dilution
of 1:200 in PBS+0.5% BSA. The cells were stained on ice with tetramer for 30 minutes
before addition of an anti-CD8-APC (clone 53-6.7, eBioscience) (without washing off the
tetramer) and incubation for another 30 minutes on ice. If the samples were not further
stained with intracellular cytokines the cells were washed and read immediately on a flow
cytometer (BD FACS Canto II).

2.10 CD107a detection
For detection of CD107a on the surface of epitope-specific TCD8+, splenocytes and PECs
were harvested as described before and plated at 2 million cells per well before stimulation
with 500 nM of IAV-derived peptide. At the same time, a 1:200 dilution of anti-mouse
CD107a-Alexa Fluor 647 (clone 1D4B, Biolegend) plus 1 μM monensin (BD GolgiStop)
was added to each well. The cells were then incubated for 5 hours in a 37ºC, 6% CO2
incubator before further staining as applicable.

2.11 In vivo killing assay
Six naive female BALB/c mice were sacrificed via cervical dislocation and then had their
spleens removed and homogenized to form a single cell suspension as previously
described. Red blood cells were removed via ACK lysis and total viable lymphocytes were
enumerated using Trypan blue staining and a hemacytometer. The cells were then pulsed
with 500 nM of the indicated IAV-derived peptide or an irrelevant peptide for 45 minutes.
The cell suspensions were then resuspended in PBS and divided into two equal aliquots of
5 mL volume. Carboxyfluorescein succinimidyl ester (CFSE) dye was added to each tube
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at a concentration of 2.5 μM (high) or 0.5 μM and incubated for 20 minutes at 37ºC with
occasional gentle mixing. Free CFSE was then neutralized by adding cold FCS to each tube
before centrifugation and an additional counting step to enumerate remaining live cells.
The high and low-pulsed splenocytes were then mixed in equal volumes and equal portions
of each population were confirmed by analysis on a flow cytometer. Once equal mixing
was confirmed the cells were resuspended in 200 μL PBS and 10 million cells were injected
into the tail vein of the recipient BALB/c mice. After 1, 2 or 4 hours the mice were
sacrificed and the splenocytes isolated as detailed earlier. For each condition, 2,000 CFSE+
events were collected.

2.12 RT-PCR of lung and BAL samples for detection of IAV
Lungs and BAL were harvested from the mice as previously described in section 2.7. In
order to measure the greatest amount of virus, the lungs and BAL were extracted and
processed on day 4 after IAV infection (13). After weighing, these samples were snap
frozen on dry ice and stored in aliquots at -80ºC until extraction of RNA. Homogenization
of the lung tissue was done using a rotor-stator homogenizer and enough diethyl
pyrocarbonate (DEPC) treated PBS to create a 10% (w/v) solution. The RNA from the lung
samples and BAL fluid was then isolated using a PureLink RNA Mini Kit (Ambion, Life
Technologies). Equal volumes of RNA solution from each sample were then reversetranscribed using SuperScript VILO cDNA synthesis kit (ThermoFisher) before using for
real-time reverse-transcription polymerase chain reaction (RT-PCR). The primers and
probe used to detect IAV matrix (M1) protein were identical to those used by the Centres
for Disease Control for universal detection of influenza A viruses (2009). GAPDH primer
and probe sets were also used to confirm that the SEB treatment is not skewing the amount
of cells in the sample. The RT-PCR reaction was run using TaqMan Fast Universal PCR
Master Mix (Applied Biosystems) using an Applied Biosystems StepOne Plus RT-PCR
system.

2.13 Detection of infectious IAV by TCID50 assay
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In order to compare the amount of infectious IAV between treatment groups, the samples
of lung and BAL homogenate were used in a 50% tissue culture infectious dose (TCID50)
assay. An aliquot of the 10% (w/v) solution of lung homogenate from mice on day 4 after
intranasal IAV infection was clarified by low speed centrifugation, and 30 μL of this
solution was set aside for the assay. Equal amounts of BAL fluid from each treatment group
was also clarified by centrifugation and set aside to be used for this assay. MDCK cells
were cultured in DMEM + 10% FCS before use in this assay. When adequate numbers of
MDCK cells had been grown, 96-well U-bottom plates were prepared for the assay by
adding 90 μL of DMEM + 0.0002% L-1-Tosylamide-2-phenylethyl chloromethyl ketone
(TPCK) trypsin (Sigma-Aldrich) to each well. Before addition of the MDCK cells, 10 μL
of lung or BAL sample was added to the first row of the plate in triplicate then serially
diluted down the columns using a multichannel pipettor. The MDCK cells were washed to
remove residual FCS, re-suspended in DMEM + 0.0002% TPCK trypsin and added to
every well (at 25,000 cells/well). The plates were then put in the incubator and the virus in
the samples was allowed to adsorb to the cells overnight. The next day, the supernatant was
removed and replaced with 200 μL of fresh DMEM + 0.0002% TPCK trypsin. Four days
later, 150 μL of supernatant was removed in each well and transferred to a new 96-well
plate before addition of 50 μL 0.5% adult chicken red blood cells in Alsever’s solution
(Charles River Avian Vaccine Services). The plates were then placed at 4ºC for 1 hour
before observation of the hemagglutination pattern of the wells. TCID50 was then
calculated using the method of Reed and Muench (14).

2.14 IAV-specific Antibody titration
After sacrificing the mice by cervical dislocation, cardiac puncture was carried out to
retrieve blood samples. These samples were then centrifuged at 17,000×g for 40 minutes
at 4ºC to isolate serum for use in antibody detection experiments. IAV-specific IgM and
IgG2b were detected using Invitrogen eBioscience Ready-SET-Go! Kits (kindly provided
by the DeKoter lab at Western University) after incubation on plates coated with IAVinfected MDCK cell lysate generated according to the protocol detailed by Benton et. al.
(15). Briefly, MDCK cells were infected with IAV (PR8) at a multiplicity of infection
(MOI) of 1:1 before harvesting 36 hours later. The cell pellet was then resuspended in PBS
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containing protease inhibitor and subjected to three freeze-thaw cycles to lyse the cells.
Enzyme-linked immunosorbent assay (ELISA) plates were then coated with this lysate
diluted 1:400 in ELISA coating buffer and blocked with PBS plus 2% FCS for 1 hour. The
plates were then washed and mouse serum samples serially diluted in ELISA assay diluent
were applied to the wells. The remainder of the assay was carried out according to
instructions supplied by the manufacturer.

2.15 Human PBMC preparation and culture
Eight healthy donors ranging in age from 21 to 39, four males and four females, were
recruited (Table 1). Selection of these donors was based on possession of the HLA-A2
allele detected via surface staining of isolated PBMCs (ThermoFisher, clone BB7.2).
PBMCs were isolated from heparinized whole blood by density gradient centrifugation
using low-endotoxin Ficoll-Paque PLUS (GE Healthcare Life Sciences). An aliquot of
PBMCs was set aside for immediate tetramer staining, and the remainder was seeded at
2106 cells/mL Roswell Park Memorial Institute (RPMI) 1640 medium containing 10%
heat-inactivated fetal calf serum, 2 mM GlutaMAX-ITM, 0.1 mM MEM nonessential amino
acids, 1 mM sodium pyruvate, 10 mM HEPES buffer, 100 U/mL penicillin and 100 µg/mL
streptomycin in a 6-well tissue culture plate. Cultures were left untreated or stimulated with
100 ng/mL SEB or with 20 ng/mL MAM. After 3 days, cells were washed thoroughly to
remove residual SAgs. The washing step was repeated on day 4, and cultures were either
halted or continued until day 7 or day 11 as indicated.
Table 1.
Seasonal flu vaccination
Donor ID

Sex

Age

within 3 months prior to
blood draw

1

M

39

Yes

2

F

28

No
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3

M

31

No

4

F

25

No

5

F

21

No

6

M

33

Yes

7

M

27

No

8

F

24

No

2.16 Dextramer and Tetramer staining of human PBMCs
The dextramer staining procedure is based off of the protocols supplied by Immudex.
Human PBMCs were enumerated and 1 million cells were put into each 12 x 75 mm
polystyrene tube for staining either individually or singly with dextramers bearing HLAA*0201+ MHCI molecules loaded with one of the following peptides: GLCTLVAML
(Epstein-Barr virus, BMLF-1280-288), GILGFVFTL (Influenza A virus M158-66),
NLVPMVATV (human Cytomegalovirus (CMV), pp65495-503) and ALIAPHAV (nonsense
peptide) as a negative control. Each sample was then surface stained with α-human CD8αFITC clone SK1 from eBioscience. Staining with both the CD8α antibody and the
dextramers was carried out according the instructions of their respective suppliers. For
most experiments, HLA-A*0201+ MHCI tetramers prepared by the NIH tetramer facility
specific for the same IAV and cytomegalovirus (CMV) epitopes (GILGFVFTL and
NLVPMVATV) were used to stain the cells on day 0, 3,7 and 11. Staining was carried out
at 4ºC for 30 minutes before adding CD8α-FITC (BD Biosciences, clone SK1, isotype
mouse IgG1κ) for an additional 30 minute incubation. Five minutes prior to analysis via
flow cytometry, 5 μL of eBioscience 7-AAD Viability Staining Solution was added per
million cells in the sample.
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Gating analysis was done by first excluding dead cells, which stain positive for 7-AAD.
After gating on the putative lymphocyte population as determined by FSC-A and SSC-A
characteristics, doublets were then excluded based on FSC-W versus FSC-H and SSC-W
versus SSC-H measurements. CD8α+ cells were then gated on and examined for tetramer
or dextramer binding.

2.17 51Cr release assay
Human HLA-A2+ T2 cells (kindly provided by Dr. Tania Watts, University of Toronto)
were pulsed overnight with 2 μM of the M158-66 peptide or vehicle for use as target cells in
the assay. The next day, these cells were washed and resuspended in 100 μL of PBS, then
labelled with 100 μCi of 51Cr in saline (Perkin-Elmer) for 1.5 hours. PBMCs that had been
cultured for 11 days with SEB (100 ng/mL) were then harvested and stained with human
Alexa Fluor 647-conjugated tetramer recognizing the M158-66 peptide in the context of
HLA-A2 as previously described. After staining, tetramer-positive cells were then isolated
by incubating with Miltenyi anti-Cy5/anti Alexa Fluor 647 MicroBeads prior to positive
selection with a Miltenyi MS column according to the manufacturer’s protocol. Columnbinding fractions were then incubated with the aforementioned T2 target cells in a 96-well
U-bottom plate at various effector:target ratios for 8 hours, after which the plate was
centrifuged and the supernatants collected. The amount of radioactive Cr in the supernatant
was then assessed using a Wallac Wizard 1470 automatic gamma counter.

2.18 Flow cytometry and analysis
All FACs data was collected using a FACs Canto II flow cytometer from BD Biosciences
and FACs Diva software. All gating and data analysis was done using Flowjo software,
version 7.6 or 10 (TreeStar).

2.19 Statistical Analyses
Statistical significance was determined where appropriate by application of a two-way
analysis of variance (ANOVA), paired or unpaired Student’s T-test using GraphPad Prism
5 software. Values of p<0.05 were considered statistically significant.
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Chapter 3: Results
3.1 In vitro stimulation of BALB/c splenocytes with SEB
decreases the detectability of TCD8+ bearing certain Vβ
regions.
It has been previously reported that SEB stimulation results in the anergy and/or deletion
of T cells (1, 2, 3). To determine if this can be observed in the context of a single stimulation
of SEB in vitro, a BALB/c mouse was sacrificed and the splenocytes were stimulated in a
tissue culture plate with 500 ng/mL of purified SEB. Three days later, at the peak of SEBinduced proliferation (4), the splenocytes were divided into separate aliquots and stained
for expression of CD8 and one of 15 different mouse Vβ regions prior to interrogation via
flow cytometry. CD8+ T cells bearing Vβ regions that bind SEB (Vβ7, 8.1/8.2 and 8.3 as
denoted by the dashed boxes in Figure 2) decreased in percentage abundance after SEB
stimulation as compared with splenocytes cultured with PBS alone. Though Vβ3 and
Vβ17a also bind SEB they are not found in BALB/c mice due to genetic deletion by
endogenous retroviruses (5). It needs to be noted that this experimental setup cannot
distinguish between a loss of staining as a result of cell death and due to TCR
internalization following T cell activation.
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Figure 2. In vitro culture of BALB/c splenocytes with SEB results in reduced
detectability of TCD8+ bearing SEB-binding Vβ regions. These data derive from
analysis of a 3-day splenocyte culture in the presence of PBS or 500 ng/mL SEB. The cells
were harvested 3 days after SEB addition and the Vβ usage by bulk TCD8+ was determined
using a BD Vβ screening kit.
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3.2 SEB alters the IAV-specific immunodominance hierarchy
in a mouse model of IAV vaccination
In BALB/c mice, the TCD8+ immunodominance (ID) hierarchy has been well
characterized (6). Most of the TCD8+ that participate in the primary response to IAV are
specific for the NP147 peptide, with the remainder of the response directed against PB2289,
HA518, NP39, HA462 and NP218 in descending order of total cell number. It has also been
established that the primary TCD8+ response to IAV administered as an i.p. injection is
greatest in magnitude (total number of IAV-specific TCD8+) after one week (7). The i.p.
route was chosen in order to initiate a measurable TCD8+ response to IAV without inducing
morbidity, which could otherwise make the interpretation of our results difficult. To
determine the effect of SEB on the IAV-specific response, 50 μg of purified SEB was
delivered as an i.p. injection 3 days before vaccination with IAV. This amount of SEB does
not induce measurable morbidity or mortality in BALB/c mice, as this strain lacks the
humanized MHC II region necessary for efficient SEB binding (8). The i.p. route also does
not result in active viral propagation, as cells in the peritoneal compartment lack sialic acid
receptors. Other studies have also established that the peak TCD8+ proliferation induced
by SEB occurs on day 3 after injection (4). To detect Ag-specific TCD8+, ICS for IFNγ
expression was utilized. This method relies on the fact that epitope-specific TCD8+ produce
IFNγ when briefly re-stimulated with their cognate peptide (9). ICS for IFNγ reliably
detects epitope-specific TCD8+ capable of making effector cytokines (10).
On day 10 post-SEB injection (day 7 after IAV injection) the mice were sacrificed and the
PECs were collected by sequential lavage. To ensure collection of adequate numbers of
cells for staining, these samples were pooled within each treatment group. The spleen was
then dissected and homogenized before both samples were assessed for IFNγ production
in response to purified peptide via ICS. The splenic TCD8+ response of mice injected with
PBS before IAV vaccination demonstrates the expected ID trend in terms of percentage
(Fig. 3A) and absolute number of epitope-specific TCD8+ (Fig. 3B). However, SEBinjected animals had significantly higher numbers of splenic TCD8+ specific for NP147,
HA518 and HA462 by percentage of TCD8+ as well as by absolute number (with the addition
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of a less striking increase in NP39-specific cells) (Fig. 3A,B). In the case of HA518-specific
TCD8+ this augmentation was sufficient to render this population subdominant only to the
NP147 response, thus altering the typical ID hierarchy to IAV. Interestingly, the
augmentation of select TCD8+ epitope-specific populations in the peritoneal cavity was
only observed in terms of absolute number of epitope-specific TCD8+ in the SEB-treated
animals, with an opposite trend being observed in terms of percentage (Fig. 3D,C).
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Figure 3. Effect of SEB on the primary TCD8+ response to IAV in BALB/c mice. (A)
Percentage of epitope-specific cells among all TCD8+ in the spleen, as detected using
intracellular cytokine staining for IFNγ expression after stimulation with cognate peptide.
(B) Absolute number of epitope-specific TCD8+ in the spleen, calculated based on total
cell counts after splenic homogenization. The equivalent (C) percentage data and (D)
absolute cell number are shown for PECs collected from mice and pooled within each
experiment. N=26 per group representing 5 independent experiments for the splenic data,
while the PEC data has a corresponding N=5. Bars represent mean +SEM (*, p<0.05, **,
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Flow cytometric evaluation of IFNγ-expressing cells can also help reveal how much
relative IFNγ is present on a per cell basis. IFNγ+ CD8+ cells from both PBS and SEB
conditions were gated on using Flowjo software and the geometric mean fluorescence
intensity (gMFI) of each population was calculated. The three most immunodominant
TCD8+ populations revealed no difference between SEB and PBS-injected animals in
terms of IFNγ production on a per cell basis (Fig. 4). This indicates that while SEB
augments the percentage and absolute number of splenic epitope-specific TCD8+, it does
not enhance or diminish the ability of a given cell to produce IFNγ.
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Figure 4. gMFI of IFNγ-FITC for three selected splenic epitope-specific populations.
The gMFI values were based off of CD8+ events that also express IFNγ in response to
peptide stimulation. The actual fluorescence value represents the average brightness of the
IFNγ-FITC staining per cell. N=23 per group representing 5 independent experiments. Bars
represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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As a control to roughly assess whether SEB impacts the ability of the mouse immune
system to respond to whole IAV rather than purified peptide, J774 macrophages were
infected with IAV before using the infected cells to stimulate TCD8+ in an ICS. The J774
cell line was chosen because it shares an MHC haplotype with BALB/c mice and is capable
of being infected with IAV (11). This experiment demonstrated that SEB augments the
percentage and absolute number of total TCD8+ that respond to IAV-infected J774 cells
(Fig. 5).
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Figure 5. Percentage (A) and absolute number (B) of TCD8+ in the spleen producing
IFNγ in response to stimulation with IAV-infected J774 cells. J774 cells were infected
with IAV for 5 hours before washing and incubating with splenocytes and PECs. N=7
(PBS) or 6 (SEB) per group, representing 2 independent experiments. Bars represent mean
+SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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Another parameter of the TCD8+ response to IAV that can be gleaned from the ICS
experiments is the effect of SEB on the total percentage and absolute number of all TCD8+,
not just IAV-specific cells. This is an additional, though indirect, control to confirm that
the SEB used is biologically active and capable of causing TCD8+ expansion. Gating on
live bulk TCD8+ demonstrated that, as is the case for total IAV-specific TCD8+, the
percentage and number of bulk TCD8+ in SEB-treated animals is significantly increased
compared to the TCD8+ response in animals injected with PBS (Fig. 6).
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Figure 6. Effect of SEB on the primary TCD8+ response to IAV in BALB/c mice. (A)
Percentage of overall TCD8+ in the spleen out of single live cells. (B) Absolute number of
total TCD8+ in the spleen, calculated based on total cell counts after splenic
homogenization. N=26 per group representing 5 independent experiments. Bars represent
mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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Though the ICS for IFNγ is a sensitive and specific assay for identifying epitope-specific
TCD8+, it is limited by the fact that only cells capable of producing IFNγ can be detected.
IAV-specific TCD8+ are all typically capable of producing IFNγ after exposure to cognate
peptide (12), but given the evidence for SEB-induced anergy (13, 14, 15) it is necessary to
validate the observed differences between PBS- and SEB-injected animals using MHC I
tetramers. Tetramer reagents are composed of four MHC molecules, each loaded with the
peptide of interest, which have been joined together into a single complex (16). This
complex is then conjugated to a fluorophore that is detectable via flow cytometry. This
reagent is capable of binding to the TCR of cells that are specific for the peptide that has
been loaded onto the tetramer. NP147- and HA518-loaded tetramers were synthesized by and
obtained from the NIH Tetramer Facility; these tetramers were chosen because they
identified the epitope-specific populations that had been significantly enhanced in number
as determined by ICS. Mice that had been injected with PBS/SEB followed by vaccination
with IAV were sacrificed to obtain splenocytes that were then stained with NP147- and
HA518-loaded tetramers, followed by surface staining for CD3 and CD8 expression. There
was a trend towards an increased percentage of tetramer+ cells among the CD3+ CD8+
compartment in the spleen for both NP147- and HA518-specific population (Fig. 7A), which
became significant when absolute splenic cell numbers were factored in (Fig. 7B). The
absolute numbers of epitope-specific cells identified via ICS versus tetramer staining were
similar, demonstrating that ICS is a reliable method for detection of epitope-specific
TCD8+ in the context of experiments with SEB.
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Figure 7. Effect of SEB on the (A) percentage and (B) number of CD3+ CD8+ epitopespecific splenocytes as determined by tetramer staining. Mice were injected with SEB
or PBS three days before injection of IAV. Seven days after IAV injection PECs and
splenocytes were harvested for tetramer staining. N=8 per group pooled from 2
independent experiments. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***,
p<0.001, unpaired Student’s t-test).
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3.3 Augmentation of the response to IAV by SEB lasts several
days after the peak TCD8+ response to IAV
Given that SEB has previously been thought to induce T cell anergy, it is possible that the
augmented IAV-specific TCD8+ response on day 7 was transient and that later time points
would reveal a loss of IAV-specific cells in the spleens of SEB-treated animals. To examine
this possibility, BALB/c mice were injected as before with SEB or PBS three days before
an i.p. vaccination with IAV, though this time the enumeration of TCD8+ specific for
different IAV epitopes was carried out on days 3, 5, 9 and 11 in addition to day 7. This
necessarily involved setting up different cohorts of mice that were sacrificed to obtain
splenocytes at each of the aforementioned time points. As before, an ICS for IFNγ
expression was carried out to examine the percentage and absolute number of cells specific
for each IAV-derived epitope. Though the variability was high due to the low number of
mice per time point, the data still shows a trend towards increased epitope-specific TCD8
by percentage (Fig. 8A) and absolute number (Fig. 8B) in the SEB-treated animals versus
those injected with PBS. For NP147 and HA518, this trend even reached statistical
significance on days 9 and 11 in terms of percentage. These time points fall far past the
time when other sources in the literature report the induction of T cell anergy/deletion by
SEB (2, 17).
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Figure 8. Primary response to IAV over the course of 11 days in PBS- versus SEBinjected animals. All mice were injected with SEB 3 days before IAV vaccination on day
0. Each time point represents data from a different cohort of 3 mice sacrificed on indicated
days. The data from each individual mouse is plotted individually to show the degree of
variation between animals. Data are expressed as (A) percentage of CD8+ cells that are
IFNγ+ after stimulation with a given peptide as well as (B) the absolute number of splenic
epitope-specific TCD8. N=3 per group. Bars represent mean ±SEM (*, p<0.05, **, p<0.01
and ***, p<0.001, unpaired Student’s t-test).
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3.4 TCD8+ expanded by SEB are functional in terms of
degranulation and cytotoxic ability
Though the ability to detect SEB-expanded IAV-specific TCD8+ by virtue of their ability
to produce IFNγ suggests that these cells are functional effectors, it is possible that SEB
renders these cells unable to carry out other functions such as degranulation and killing of
IAV-infected cells. Expansion of a population does not always result in enhanced function
(18), and given the established negative effect of SEB on the ability of CD4+ T cells to help
B cells produce antibodies (19) the effect of SEB on TCD8+ function needed to be
elucidated. TCD8+ are capable of killing cells through the perforin-granzyme pathway,
which involves the release of cytotoxic granules from an activated TCD8+ (20). Granule
exocytosis in response to stimulation with a cognate peptide results in the expression of
CD107a on the surface of the T cell (21). To assess the effect of SEB on the ability of IAVspecific TCD8+ to degranulate, splenocytes from mice that had been treated as before with
PBS/SEB and IAV were pulsed with peptide in a modified ICS. At the start of the
incubation with peptide, an anti-CD107a fluorescent Ab was added, enabling labelling to
occur as soon as CD107a appeared on the cell surface. In addition, monensin was added to
prevent surface CD107a from recycling back into the cell. As shown in Figures 9A and B,
splenic TCD8+ from SEB-treated animals had a higher percentage and absolute number of
CD107a-expressing cells than mice treated with PBS for all but one of the epitope-specific
populations examined. This means that SEB is not inhibiting TCD8+ degranulation; rather,
there is a significant increase in the SEB-inoculated animals as compared to PBS-treated
mice for both parameters. Interestingly, the data suggest the opposite may be true when
considering the amount of degranulation that takes place on a per cell basis. The gMFI of
CD107a, or the amount of CD107a expressed per cell, was significantly decreased in the
SEB animals when considering the NP147- and NP39-specific TCD8+ populations.
However, the absolute decrease in gMFI is minute, which may indicate that this difference
is not biologically meaningful.
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Figure 9. SEB increases the percentage and absolute number of IAV-specific TCD8+
expressing CD107a. Splenocytes were stimulated with IAV-derived peptide for 5 hours
in the presence of anti-CD107a antibody before surface staining for CD3 and CD8,
followed by intracellular staining for IFNγ. (A) Percentage and (B) absolute number of
CD3+ CD8+ splenocytes that co-express IFNγ and CD107a. (C) CD107a-based gMFI was
also calculated for quadruple+ cells. N=3 per group. Bars represent mean ±SEM (*, p<0.05,
**, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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In terms of the primary TCD8+ response to IAV, perhaps the most biologically relevant
readout for function is the ability of IAV-specific cells to kill their target cells in vivo. This
can be accomplished in a mouse model using a CFSE-based in vivo killing assay that
measures epitope-specific killing by TCD8+ based on the disappearance of peptide-pulsed
cells that had been labelled with CFSE and injected into mice (22, 23). To measure the
effect of SEB on the killing of NP147- and HA518-pulsed target cells by splenic TCD8+ in
vivo, BALB/c mice were injected with SEB or PBS three days before vaccination with
IAV, as had been done in ICS and tetramer experiments (Fig. 3, Fig. 7). On day 7 after
IAV injection, the mice were injected via the tail vein with cells that had been pulsed with
an irrelevant peptide, NP147, or HA518 and labelled with various concentrations of CFSE
before the cells were washed and mixed in equal numbers. After 4 hours, the mice were
sacrificed and the splenocytes harvested for interrogation via flow cytometry. Increased
killing results in a smaller CFSE peak in terms of cell number, and this difference is
quantified and normalized based on the size of the peak corresponding to the cells pulsed
with irrelevant peptide as well as naive mouse controls. Even though by 4 hours, the killing
of NP147-pulsed cells in both PBS- and SEB-treated mice appeared to have reached
saturation, there was significantly increased killing directed against the HA518-pulsed cells
in the SEB-injected animals versus the PBS-injected mice (Fig. 10A). This was visible
even without calculation based on the size of the peaks as they appeared on the flow
cytometer (Fig. 10B). These results demonstrate that SEB administration augments the
TCD8+ cytotoxic response to IAV vaccination in vivo.
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Figure 10. Lytic ability of splenic epitope-specific TCD8+ after 4 hours of incubation
in vivo. Splenocytes from naive donor BALB/c mice were pulsed with indicated peptides
prior to labelling with CFSE. The cells were then washed and mixed in equal numbers
before injection into mice that had been treated with PBS or SEB prior to IAV inoculation.
Four hours later, the animals were sacrificed and the amount of killing determined by
comparison of CFSE peak size to naive control mice. Killing was calculated using the
following formula: {1-[(% IAV peptide-pulsed cells in primed mouse / % irrelevant
peptide-pulsed cells in primed mouse) / (% IAV peptide-pulsed cells in naive mouse / %
irrelevant peptide-pulsed cells in naive mouse)]} × 100. The killing shown in (A) was
determined after a 4-hour incubation after injection. Typical CFSE peaks are shown in (B).
N=4 per group, data pooled from 2 independent experiments. Bars represent mean +SEM
(*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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3.5 SEB increases the magnitude of the IAV-specific TCD8+
response regardless of the IAV strain used for vaccination
All experiments thus far involved the use of PR8 as the vaccination strain. This lab-adapted
IAV strain is common for laboratory use as it is highly adapted for use in mice and for
propagation in eggs (24). It is also only mildly pathogenic in the case of accidental human
infection (25). This high degree of adaptation raises the question of whether or not SEB
would have the same effect on a TCD8+ response induced by other IAV strains, including
those more relevant for human illness. Therefore, the ICS experiment examining the effect
of SEB on the primary response to vaccination with IAV (PR8) was repeated with four
different IAV strains (Fig. 11A). Though the strains I utilized share a PR8-derived core
they differ in their expression of surface membrane molecules such as HA and NA. Both
J1 and X31 are artificial strains; J1 is an H3N1 PR8 reassortant (26) while X31 (27) is an
H3N2 strain. NT60 and HK are both derived from naturally circulating viruses, with both
representing seasonal H3N2 strains (28). Despite the differences between these viruses,
SEB produced the same effect with the four test strains in terms of significantly increasing
the response to NP147 (Fig. 11B-E)
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Figure 11. Primary splenic TCD8+ response to different strains of IAV after SEB
treatment, as determined by ICS for IFNγ expression. BALB/c mice were injected with
SEB or PBS three days before i.p. injection with either X31, J1, NT60 or HK. Seven days
later IFNγ expression by splenocytes in response to incubation with IAV-derived peptides
was measured via ICS. (A) Depicts the different HA and NA proteins of each of the
indicated strains in the context of the common PR8 viral core. Both (B) and (C) represent
the absolute number of epitope-specific TCD8+ produced in response to vaccination with
artificially-created lab strains of IAV, while (D) and (E) show the same response elicited
by naturally circulating IAV strains. N values are indicated on each graph separately, while
the bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s
t-test).
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3.6 SEB administration before infection with recombinant
vaccinia virus reduces the number of VV-specific TCD8+
The large changes in terms of the IAV-specific ID hierarchy induced by SEB
administration raises the question of whether the same effect would be observed when
IAV-derived peptides are presented in the context of a different virus. To answer this
question, BALB/c mice in two separate experiments were given PBS or 50 μg SEB i.p.
three days before infection with 5 million pfu of rVV encoding NP147 or HA518. Seven days
after infection, at the peak of the TCD8+ response to rVV, the percentage and number of
TCD8+ specific for epitopes derived from rVV and IAV were investigated via ICS for
IFNγ. Interestingly, the epitope-specific TCD8+ recovered from the spleens of animals
infected with rVV-NP147 were reduced in terms of percentage (Fig. 12A) and absolute
number (Fig. 12B) for both the vaccinia epitopes and NP147. The same pattern was observed
for the percentage (Fig. 12C) and absolute number (Fig. 12D) of splenic TCD8+ recovered
from mice infected with rVV-HA518.
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Figure 12. The TCD8+ response to vaccinia virus is reduced by administration of SEB.
BALB/c mice were injected with PBS or 50 μg of SEB before i.p. infection three days postinfection with 5 million pfu of a recombinant vaccinia virus expressing NP147 or HA518
peptide as a cytosolic minigene. At the peak of the TCD8+ response, the mice were
sacrificed and the percentage and number of TCD8+ specific for both IAV- and VV-derived
epitopes were determined via ICS. (A) The percentage and (B) number of epitope-specific
TCD8+ elicited in response to rVV encoding NP147 are shown for immunogenic VV
peptides and for NP147. The equivalent data are shown for the (C) percentage and (D)
absolute number of TCD8+ in elicited in response to rVV encoding HA518. N=4 per group.
Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s
t-test).
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3.7 Changes in the ID hierarchy are driven by Vβ expression
among different TCD8+ populations
One question that remained from the primary ICS experiments shown in Figure 3 was the
explanation for why some epitope-specific TCD8+ populations (such as those recognizing
NP147 and HA518) were expanded by SEB administration while others (such as those
recognizing PB2289) were not. Since SEB is known to preferentially bind certain Vβ regions
(29), it is possible that responsive populations predominantly express TCRs that use SEBreactive Vβ regions. To test this idea the primary ICS in BALB/c mice was repeated, this
time examining the response to only one epitope per experiment. This enabled staining in
parallel for 15 different mouse Vβ regions so as to determine the Vβ usage by IFNγ+ cells.
For each animal the total proportion of cells that stained positive for a given Vβ out of the
total population of epitope-specific cells with a detectable Vβ region was determined (Fig.
13). The epitope-specific populations that were expanded by contact with SEB (NP147 and
HA518) were dominated by the expression of SEB-reactive Vβ regions, while those that
were not expanded (PB2289) showed no such skewing. This strongly suggests that the
expansion of certain populations is due to their predominant usage of a Vβ region that can
bind SEB.
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Figure 13. Expression of different Vβ regions among splenic TCD8+ specific for three
different epitopes. The Vβ makeup of each epitope-specific population was determined
by co-staining for IFNγ and Vβ expression. The proportion of each epitope-specific
population that expressed a given region was then calculated as a proportion of the whole
for each individual mouse. Each bar represents data from a different animal, with the darkshaded segments denoting Vβ regions that are known to bind SEB.
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If the changes observed during the primary response to IAV are dependent on the
differential expression of Vβ regions among epitope-specific TCD8+, then use of a different
SAg that binds the same Vβ regions as SEB should produce similar ID changes when
administered before IAV. MAM is one such SAg. It also has the advantage of binding
mouse MHC with higher affinity than many SAgs derived from S. aureus (30, 31). Of
particular relevance is the fact that MAM binds Vβ8, which corresponds to the main family
of Vβ found in the NP147- and HA518-specific TCD8+ populations. As before, mice were
injected i.p. with 50 μg of MAM three days before i.p. injection of IAV. ICS to enumerate
epitope-specific TCD8+ revealed that mice having received MAM had an elevated
percentage of NP147-specific cells (Fig. 14A). By absolute number both NP147- and HA518specific populations (as well as NP39) were significantly elevated in MAM-injected animals
as compared to animals that received PBS, with no such increase observed for PB2289specific cells (Fig. 14B). This result recapitulates the pattern found in SEB-injected
animals, suggesting that SAg Vβ specificity is driving the ID changes observed in the i.p.
vaccination model.
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Figure 14. Administration of MAM augments the primary TCD8+ response to IAV in
a similar manner as SEB. Mice were injected i.p. with 50 μg MAM or PBS three days
before injection of IAV. (A) Percentage of epitope-specific cells among all TCD8+ in the
spleen, as detected using intracellular cytokine staining for IFNγ expression after
stimulation with cognate peptide. (B) Absolute number of epitope-specific TCD8+ in the
spleen, calculated based on total cell counts after splenic homogenization. N=8 for the PBS
condition and N=7 for the MAM condition; data are pooled from 2 independent
experiments. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001,
unpaired Student’s t-test).
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If the augmentation of the NP147 and HA518 responses after contact with MAM and SEB
were due to high expression of Vβ8, then the same ID changes should not be observed after
administration of a SAg that targets different Vβ. One such SAg is SEA, which binds Vβ1,
3, 10, 11 and 17 (32). Though both Vβ3 and Vβ17 are SEB-reactive, they are not expressed
in BALB/c mice due to genetic deletion by endogenous retroviruses (33). Separate cohorts
of mice were injected according to the primary vaccination protocol, replacing injection of
50 μg SEB with 50 μg of SEA by the i.p. route, followed by i.p. injection of IAV. Analysis
of epitope-specific populations by ICS showed that SEA produced no skewing of the ID
hierarchy as judged by either the percentage of epitope-specific cells (Fig. 15A) or by their
absolute numbers (Fig. 15B). This demonstrates that administration of a SAg that does not
target the Vβ regions predominantly expressed by IAV-specific TCD8+ is unable to cause
skewing of the ID hierarchy.
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Figure 15. SEA administration does not change the IAV-specific TCD8+ ID hierarchy.
Mice were injected i.p. with 50 μg of SEA three days before vaccination with an i.p. dose
of IAV. (A) Effect of SEA on the percentage of IAV-specific TCD8+ and (B) absolute
number of epitope-specific TCD8+. N=4 for each condition. Bars represent mean +SEM
(*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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3.8 Changing the order of IAV and SEB administration results
in increased TCD8+ responses towards all epitopes.
Since bacterial superinfection is known to occur in patients hospitalized with IAV
infection, additional experiments reversing the order of IAV/SAg exposure were
performed. The objective was to examine what effect vaccinating with IAV before
injection of SAg may have on the TCD8+ response to IAV. As before, these experiments
were carried out in a BALB/c mouse model of primary i.p. IAV vaccination. IAV was
injected i.p. four days before an i.p. dose of 50 μg SEB, after which three more days were
allowed to elapse before the mice were sacrificed and an ICS carried out to enumerate the
percentage and number of IAV-specific TCD8+. The design of this experiment was such
that the peak of the TCD8+ response to IAV and proliferation induced by SEB fell on the
same day. In this case the percentage (Fig. 16A) and absolute number (Fig. 16B) of splenic
TCD8+ specific for almost all of the epitopes in the ID hierarchy were significantly
increased, not just the epitope-specific populations that predominantly express TCRs with
an SEB-reactive Vβ region. Despite the vigorous TCD8+ response, the mice displayed no
morbidity aside from slightly ruffled fur.
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Figure 16. Effect of SEB administration on the primary splenic TCD8 + response to
IAV, where SEB is administered 3 days before the peak IAV-specific response. Mice
were injected i.p. with IAV. On day 4 after IAV inoculation the mice were injected with
SEB or PBS. An ICS for IFNγ expression was carried out on day 7 after IAV injection to
examine the (A) percentage and (B) absolute number of splenic IAV-specific TCD8+ for
each detectable epitope-specific population. N=8 per group, pooled from 2 independent
experiments. Bars represent represent mean +SEM (*, p<0.05, **, p<0.01, ***, p<0.001
and ****, p<0.0001, unpaired Student’s t-test).
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Given the evidence from Figure 16 that SEB does not induce deletion or anergy of IAVspecific TCD8+ when administered after IAV vaccination, it was relevant to ask whether
SEB could be used to prolong the TCD8+ response to IAV. In this case IAV was
administered to BALB/c mice as for Figure 16, except that SEB was injected on day 7 after
IAV vaccination rather than on day 4. The effect of these interventions was then assayed
via ICS three days later, which corresponds to day 10 post IAV injection. At this time point,
the TCD8+ response to IAV should be diminishing. Though the magnitude of the IAVspecific TCD8+ response was indeed slightly smaller than what is shown in Figure 16, there
remained a statistically significantly increased response to some IAV epitopes as measured
by the percentage (Fig. 17A) and for all epitopes by absolute numbers (Figure 17B) save
for NP218. This shows that SEB injection after IAV exposure can be used to prolong a
strong TCD8+ to IAV vaccination.
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Figure 17. Effect of SEB administration on the primary splenic TCD8+ response to
IAV, where SEB is administered during the peak IAV-specific response. Mice were
injected with IAV i.p. 7 days before administration of SEB or PBS. Three days after this
second injection an ICS for IFNγ expression was carried out to examine the effect of SEB
on the (A) percentage and (B) absolute number of splenic IAV-specific TCD8+. N=8 per
group, pooled from 2 independent experiments. Bars represent mean +SEM (*, p<0.05, **,
p<0.01, ***, p<0.001 and ****, p<0.0001, unpaired Student’s t-test).
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Though the increased magnitude of the response shown in Figure 17 is remarkable, it must
be confirmed that these expanded TCD8+ are functional in terms of their cytotoxic
capability. Fortuitously, the augmentation of the TCD8+ response by SEB was the greatest
in magnitude for the dominant epitope NP147, which makes the NP147-specific TCD8+
response the most suitable choice for assessment of the effect of SEB on cytotoxic function.
BALB/c mice were injected with IAV i.p. before receiving either PBS or 50 μg SEB i.p.
seven days later, followed by an in vivo killing assay examining NP147-pulsed cells after
three days. As an additional condition the mice were sacrificed 1, 2 or 4 hours after
injection of pulsed target cells to track the rate of killing in PBS- versus SEB treated
animals. At all time points the killing of NP147-pulsed target cells was significantly greater
in SEB-treated mice than in PBS-treated mice (Fig. 18). The time course also showed that
this function was extremely rapid, with the killing of target cells in the SEB-injected
animals being close to complete after just 4 hours of incubation.

107

Figure 18. The kinetics of NP147-specific CD8+ T cell-mediated cytotoxicity in PBSand SEB-treated mice. Splenocytes from naive donor BALB/c mice were pulsed with the
indicated peptide prior to labelling with CFSE. The cells were then washed and mixed in
equal numbers before injection into mice that had been injected with PBS or SEB on the
same day as the peak TCD8+ response to primary IAV administration. This assay was
carried out 3 days after that injection, a total of 10 days after initial IAV administration.
N=4 per group pooled from 2 independent experiments. Bars represent mean +SEM (*,
p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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3.9 The effect of SEB in a prime-boost model of IAV
vaccination depends on SEB administration time
Having shown that SEB augments the magnitude of the primary TCD8+ response to IAV,
it remained to be seen whether SEB was beneficial in the context of prime-boost
vaccination strategies. These strategies involve administration of a vaccine in two separate
doses to first create a primary immune response and then to create a boosted secondary
response by re-vaccinating one month later. To assess whether SEB may be useful in this
context, NP147- and HA518-tetramer-positive TCD8+ were examined for their expression of
KLRG1 and CD127 at the peak of the primary response to IAV. The timing of injections
used for this experiment was the same as in Figure 3, as this experiment could be extended
later to mimic the administration of SEB before a priming dose of IAV vaccine. KLRG1+
CD127- TCD8+ cells are characterized as terminal effectors, while KLRG1- CD127+
TCD8+ cells are considered memory precursors (34). Effective vaccination relies on the
generation of memory precursors (35). Encouragingly, while the percentage (though not
absolute number) of terminal effector TCD8+ specific for both NP147 and HA518 were
reduced in SEB-injected animals, the percentage and absolute number of memory
precursors were significantly increased in the same animals (Fig. 19).
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Figure 19. SEB administration 3 days before IAV vaccination greatly increases the
percentage and absolute number of KLRG1- CD127+ memory precursor cells that are
specific for NP147 and HA518, as determined by tetramer staining. Mice were injected
with SEB or PBS three days before i.p. injection of IAV. Splenocytes were then harvested
on day 7 after IAV injection and stained with NP147- and HA518-specific tetramers before
co-staining for KLRG1 and CD127 expression. N=4 per group. Bars represent mean +SEM
(*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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Given that injection of SEB increases the number of memory precursors during the primary
response to IAV vaccination, it stands to reason that the secondary response to IAV in mice
injected with SEB before priming could also be increased. I used an experimental primeboost vaccination regimen for IAV-specific immunity in BALB/c mice. Accordingly, I
primed mice with an i.p. injection of IAV (PR8) one month before a boosting dose of IAV
(SEQ.12) was given (36, 37). Since IAV (SEQ.12) was created by serial passage of PR8 in
the presence of several neutralizing antibodies (38), this virus escapes neutralization by the
PR8-specific antibodies present in the mouse after priming and thus can induce a robust
TCD8+ recall response. The magnitude of this recall response is typically measured one
week after boosting with SEQ.12. BALB/c mice that were treated with SEB before priming
had significantly increased percentage (Fig. 20A) and absolute number (Fig. 20B) of NP147and HA518-specific TCD8+. Therefore, the impact of SEB on the TCD8+ response can
persist for more than a month after SEB exposure.
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Figure 20. SEB administration before a priming dose of IAV (PR8) selectively
increases the TCD8+ response to IAV as measured 7 days after a booster vaccination
with IAV (SEQ.12). The mice were injected with PBS or SEB 3 days before IAV (PR8)
injection. Thirty days after the initial IAV injection the mice were given a boosting dose
of IAV (SEQ.12). One week after the booster injection the mice were sacrificed and the
(A) percentage and (B) absolute number of splenic IAV-specific TCD8+ was measured by
ICS for IFNγ. N=8 per group pooled from 2 independent experiments. Bars represent mean
+SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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Though SEB exposure increases the magnitude of the TCD8+ recall response when given
before a priming dose of IAV, this may not be the case if SEB is given during a different
phase of the recall response. Accordingly, BALB/c mice were injected i.p. with IAV (PR8)
and given a booster vaccination of IAV (SEQ.12) one month later. This time however, an
injection of PBS or 50 μg of SEB was administered three days before the booster shot, or
27 days after priming with IAV. As before, the percentage and number of IAV-specific
TCD8+ were assessed by ICS for IFNγ one week after boosting. Unexpectedly, the
percentage (Fig. 21A) and absolute number (Fig. 21B) were significantly decreased for
every IAV-derived TCD8+ epitope save for the barely-detectable NP218-specific
population.

113

Figure 21. SEB administration before a boosting dose of IAV (SEQ.12) decreases the
TCD8+ response to IAV as measured 7 days later. The mice were primed with IAV
(PR8) one month before boosting with IAV (SEQ.12). Three days before the boost the
mice were injected with SEB or PBS. One week after boosting the (A) percentage and (B)
absolute number of cells were measured by ICS for IFNγ. N=12 per group pooled from 3
independent experiments. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and ***,
p<0.001, unpaired Student’s t-test).
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To dissect what was occurring with the TCD8+ when SEB was given before the boosting
dose of IAV (and why there was such a striking reduction in the magnitude of the TCD8+
response to all IAV-derived epitopes), tetramer staining for NP147- and HA518-specific cells
was carried out in conjunction with staining for detection of proliferation, death and
anergy/exhaustion markers. Though neither epitope-specific TCD8+ population
significantly upregulated PD-1 expression, the gMFI of Fas and LAG3, associated
respectively with death and exhaustion, was significantly increased (Fig. 22) (39, 40). In
addition, the intracellular expression of Ki67, which marks proliferation (41), was
significantly reduced in TCD8+ specific for both epitopes. This demonstrates that SEB
exerts different effects on TCD8+ specific for IAV dependant on the phase of the recall
response.
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Figure 22. Splenic TCD8+ specific for NP147 and HA518 display increased expression
of anergy markers and lower Ki67 expression when SEB is given before the boosting
dose of IAV. Seven days after the boosting dose of IAV splenocytes were stained with
NP147 and HA518-specific tetramers in conjunction with a cocktail of fluorescent antibodies
directed against indicated anergy, death and proliferation markers. The gMFI for each of
these markers was determined for the tetramer+ populations for both the PBS and SEBinjected animals. N=4 per group. Bars represent mean +SEM (*, p<0.05, **, p<0.01 and
***, p<0.001, unpaired Student’s t-test).
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3.10 Local TCD8+ responses to intranasal IAV infection are
not negatively affected by SEB.
SEB, when injected locally into the peritoneal cavity, can nevertheless exert a systemic
effect (42). Therefore, an i.p. injection of SEB may influence TCD8+ responses in distant
sites such as the lungs. Since IAV naturally manifests as an upper respiratory infection, it
is possible that SEB introduced i.p. may affect IAV-specific TCD8+ responses in the lungs
and airway. To model the effect of i.p. SEB on the pulmonary TCD8+ response to IAV,
BALB/c mice were injected with PBS or 50 μg of SEB before infection with a sub-lethal
dose of IAV delivered intranasally. The mice were then monitored for weight loss until the
peak IAV-specific TCD8+ response on day 10 (43), after which they were sacrificed to
obtain cells from the spleen, lungs and bronchoalveolar lavage (BAL) fluid. Without IAV
infection, i.p. SEB alone did not induce any significant weight loss as compared to
uninfected, PBS-injected control mice (Fig. 23). Both the PBS- and SEB-injected mice that
were infected with IAV lost significantly more weight than uninfected mice, though
injection with SEB had no effect on weight loss in the IAV-infected group.
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Figure 23. Weight loss of BALB/c mice infected intranasally with a sublethal dose of
IAV (PR8) or PBS three days after intraperitoneal injection of SEB or PBS.
Uninfected and SEB-only mice were intranasally instilled with 25 μL of PBS alone to
control for inoculum volume. Mice were euthanized if weight loss exceeded 20% of their
starting weight. Each point represents mean of percent starting weight for mice in each
group ±SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, Two-way ANOVA).
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Injection of SEB had a modest effect on IAV-specific primary TCD8+ responses in the
spleen, significantly increasing the number of NP147-specific TCD8+ and decreasing the
response to the two most subdominant epitopes (Fig. 24A). However, there was no
significant difference in the numbers of IAV-specific TCD8+ in either the lungs (Fig. 24B)
or BAL (Fig. 24C) of SEB- versus PBS-treated mice. While SEB was clearly able to exert
systemic effects in this model (as shown by the changes to splenic TCD8+ numbers), local
TCD8+ responses to IAV infection in the context of replicative IAV infection were
unaffected.
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Figure 24. Response to IAV infection in the spleen, lungs and BAL of BALB/c mice
treated with PBS or SEB prior to virus exposure. Mice were infected with a sublethal
dose of IAV 3 days after SEB or PBS injection. Ten days after IAV infection the spleen,
lungs and BAL were collected from the mice for enumeration of IAV-specific TCD8+ using
ICS for IFNγ expression. (A) Splenic data is representative of the absolute number of
epitope-specific cells. Both the (B) lung and the (C) BAL data represent pooled samples
from 5 experiments. The N value varies per group (see legends), pooled from 5 independent
experiments. Bars represent mean +SEM (*, P<0.05, **, P<0.01 and ***, P<0.001,
unpaired Student’s t-test).
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Though there was no effect of SEB on the amount of IAV-specific TCD8+ in the lungs or
BAL, it is possible that SEB-induced changes to TCD8+ function could be manifested in
terms of changes in IAV titre within the lungs and airways. Accordingly, the effect of SEB
injected i.p. on viral titre in the lungs was assessed on day 4 post-infection, when viral titres
should be at their highest (44). Measurement of IAV titre is complicated due to IAV
infection resulting in the production of a high number of non-infectious viral particles (45).
Thus, viral titre was quantified using methods that detect infectious particles as well as
methods that detect total particle release. To enumerate the former, diluted preparations of
BAL and lung homogenate were used in a TCID50 assay, which quantifies relative amounts
of infectious virus per unit of starting material (46). This assay relies on the ability of IAV
to infect monolayers of MDCK cells, which also allow virus release after infection (47).
The viral progeny can be detected by the ability of particles collected from culture
supernatants originating from the infected monolayers to induce agglutination of chicken
red blood cells (48). Though infectious virus was detectable in samples from both PBSand SEB-treated animals, there was no significant difference in the amount of infectious
virus (Fig. 25).
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Figure 25. IAV titre in the lungs and BAL fluid of mice infected 4 days prior with IAV
(PR8). Three days before infection the mice were given PBS or SEB i.p. Titre was assessed
by the ability of increasing dilutions of BAL or lung homogenate to infect a monolayer of
MDCK cells. The presence of virus after washing, incubation and infection was determined
by the ability of the culture supernatant to induce agglutination of chicken red blood cells.
N=10 per group, pooled from 3 independent experiments. Bars represent mean ±SEM (*,
p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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The same samples from the lung and BAL were also subjected to RT-PCR to detect copies
of the viral m1 gene, which is generally carried as one copy per virus (49). In addition, the
M1 protein is more highly conserved than outer membrane proteins like HA or NA as even
small changes to critical residues affects its function (50, 51). RT-PCR can detect both
infectious and non-infectious particles, which could reveal if SEB treatment increased
release of defective virus particles. The amount of starting material used in the reaction
was normalized based on volume (BAL) or weight (lung tissue) before extraction of total
RNA from the samples. Similar to the quantification of infectious virus, there was no
significant difference in the amount of total virus detectable in the PBS- versus SEB-treated
mice (Fig. 26). These results indicated that i.p. SEB administration had no effect on the
ability of the BALB/c mouse immune system to control viral titre.
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Figure 26. Relative number of IAV viral particles in the lung and BAL of mice
infected with sublethal IAV (PR8) after i.p. injection of SEB. Mice were injected with
PBS or SEB 3 days before intranasal infection with IAV. Four days after infection the mice
were sacrificed to obtain lungs and BAL fluid. RT-PCR for the presence of the viral m1
gene was carried out these samples, which were the same as those used to evaluate
infectious viral titre in Figure 25. N=10 per group, from 3 independent experiments. Bars
represent mean ±SEM (*, P<0.05, **, P<0.01 and ***, P<0.001, unpaired Student’s t-test).
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To confirm that the SEB stock used for the intranasal IAV experiments could be used to
recapitulate previously reported effects on TCD4+ responses (19), BALB/c mice were
injected with PBS or SEB i.p. before i.n. infection with 0.3 MLD50 IAV. Three weeks later
the mice were sacrificed and bled through cardiac puncture to obtain blood samples. The
serum from each mouse was then isolated before being investigated for the amount of IAVspecific IgM and IgG2b present using an ELISA. IAV-specific IgM is present in the blood
before IAV infection and should be detectable regardless of experimental treatment (52).
IAV-specific IgG2b is only detectable in the serum after IAV infection and is capable of
neutralizing IAV (53). Plates were coated with IAV-infected MDCK cell lysate before
serum samples were applied. Equal amounts of IAV-specific IgM were found in samples
from both treatment groups (Fig. 27A), which was expected since mice have pre-formed
IgM that can bind IAV (54). In contrast, at most dilutions the titre of IAV-specific IgG2b
was significantly decreased in the SEB-injected mice as compared to those injected with
PBS (Fig. 27B). This observation matches what had been previously reported for the effect
of SEB on the ability of TCD4+ to provide help for Ab production (19).
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Figure 27. Antibody titres in the serum of mice treated with SEB or PBS before IAV
infection (0.3 MLD50). Three weeks after IAV infection, the mice were bled and the serum
collected for use in an ELISA. The plates were coated with IAV-infected MDCK lysate
before incubation with the diluted serum samples, after which the binding of (A) IgM or
(B) IgG2b was determined. N=8 for each group. Bars represent mean ±SEM (*, p<0.05,
**, p<0.01 and ***, p<0.001, 2-way ANOVA).
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3.11 SEB greatly augments the immunodominant NP147
response in the context of IAV-specific memory.
While primary and recall TCD8+ responses are augmented by SEB administration (with
the notable exception of scenarios in which SEB is given before boosting with SEQ.12),
an important component of the immune response when considering anti-IAV immunity is
the memory phase. IAV is a common pathogen, and in terms of human immunity most
individuals will have a pre-existing pool of memory TCD8+ specific for IAV. However,
since IAV is not a natural mouse pathogen, experimental models utilizing mice necessitate
induction of memory through IAV exposure before a response can be detected. The mouse
TCD8+ response to IAV is largely directed against the immunodominant NP147 epitope
(55), and our initial experiments demonstrated that the memory response is almost entirely
directed at this epitope. To determine the effect of i.p. SEB injection on this memory
response to IAV, BALB/c mice were vaccinated with IAV i.p. and left to develop a CD8+
memory population for 2 months. At the end of this period the mice were injected with
PBS or 50 μg SEB i.p., followed three days later by sacrifice and harvesting of splenocytes.
Even two months after injection, SEB was able to significantly expand the number of
NP147-specific splenic TCD8+ (Fig. 28).
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Figure 28. The NP147- specific memory CD8+ T cell population is expanded by
contact with SEB. Mice were injected with IAV i.p. 2 months before injection of SEB.
Three days after SEB/PBS injection, NP147-specific TCD8+ responses were measured via
ICS for IFNγ. N=16 per group, pooled from 4 independent experiments. Bars represent
mean +SEM (*, p<0.05, **, p<0.01 and ***, p<0.001, Student’s t-test).
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A separate cohort of IAV memory mice were used to assess the killing ability in vivo of
these SEB-expanded NP147-specific TCD8+. As before, BALB/c mice were injected with
IAV i.p. two months before injection of PBS or SEB i.p. On the flow cytometer, the CFSE
peak corresponding to the NP147-pulsed target cell population was noticeably smaller in the
samples from the SEB-treated mice as compared to those from the PBS-treated animals
(Fig. 29A). Calculation of the percent specific killing of NP147-pulsed target cells showed
a statistically significant increase for the SEB-injected animals as compared to those that
had received PBS three days prior (Fig. 29B). These results demonstrate that SEB is
capable of augmenting the magnitude as well as cytotoxic effector capability of memory
IAV-specific TCD8+.
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Figure 29. IAV memory mice injected with SEB three days prior to in vivo killing
assay have significantly more killing of NP147-pulsed target cells. Mice were injected
i.p. with IAV before resting for 2 months. The animals were then injected with PBS or SEB
3 days before evaluation of NP147-specific cytotoxicity by in vivo killing assay. (A)
Representative CFSE peaks from PBS- and SEB-injected IAV memory mice. The NP118
(irr) peak represents splenocytes that had been pulsed with the immunodominant peptide
from lymphocytic choriomeningitis virus (LCMV), which are not killed by TCD8+ in the
experimental mice. (B) Quantification of percent specific killing based on loss of
fluorescence from NP147-pulsed target cells. N=7 for PBS and N=6 for SEB, pooled from
3 independent experiments. Bars represent mean ±SEM (*, p<0.05, **, p<0.01 and ***,
p<0.001, unpaired Student’s t-test).
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3.12 Human IAV-specific memory responses are augmented
by SEB.
Similar to the IAV-specific memory response in the BALB/c mouse model, the human
memory TCD8+ response in HLA-A2+ individuals is largely directed against one epitope,
abbreviated here as M158 (56). Since IAV is a natural human pathogen, almost every
individual in the human population will have come into contact with IAV and thus have a
population of memory TCD8+ specific for the virus. In addition, other studies have shown
that the M158-specific cell population in HLA-A2+ individuals (who comprise a large
proportion of the Caucasian population (57)) largely uses the Vβ17 region in the TCR (58).
This Vβ region binds SEB with high affinity (59), potentially making M158-specific
memory TCD8+ highly susceptible to SEB-induced activation and proliferation. PBMCs
were isolated from healthy HLA-A2+ individuals by density gradient centrifugation before
culture with SEB and interrogation with M158 tetramer on days 0 (freshly isolated), 4, 7
and 11. The sample plots shown in Figure 30A shows the typical course of the in vitro
response to SEB, quantified in terms of percentage in Figure 30B and in terms of absolute
number in Figure 30C. M158-specific TCD8+ appear to be reduced in terms of absolute
number when the population is detected by tetramer staining on day 4. However, this
population is increased relative to PBS on day 7 and greatly expanded by day 11,
suggesting that this loss of detection is due to internalization of the TCR rather than
deletion or anergy.
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Figure 30. Human M158-specific memory TCD8+ are expanded by SEB. Purified
PBMCs were stimulated with either PBS or SEB on day 0 followed by staining for CD3
and CD8 along with M158 tetramer. This staining was repeated on day 4, 7 and 11, with
washes being carried out to remove residual cytokine and SEB on day 3 and 4. (A) Sample
FACs plots from one donor. (B) Fold change of M158-specific memory TCD8+ based on
percentage of the total TCD8+ population and by (C) total number per million cells. N=8
per group pooled from 8 independent donors. Bars represent mean +SEM (*, p<0.05, **,
p<0.01 and ***, p<0.001, unpaired Student’s t-test).
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To determine if other SAgs that bind human Vβ17 can result in the same expansion of
M158-specific memory TCD8+, PBMCs from four HLA-A2+ donors were isolated and
used in an analogous experiment utilizing MAM instead of SEB. MAM binds to and
activates human Vβ17+ cells, even though this SAg is derived from a mouse-adapted
pathogen (60). Though the results did not reach statistical significance, there is a trend
towards an expansion of the M158-specific population in the MAM-treated group versus
the PBS-treated control similar to that observed in the experiments using SEB (Fig. 31).
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Figure 31. M158-specific memory CD8+ T cells from healthy human donors expand
in the presence of MAM SAg. PBMCs were harvested and cultured with MAM or vehicle
control for 11 days. Staining for M158-specific cells was carried out as for Figure 29. Fold
change is expressed relative to the percentage of freshly isolated M158 tetramer positive
cells. N=4 per group pooled from 4 independent donors. Bars represent mean ±SEM (*,
p<0.05, **, p<0.01 and ***, p<0.001, unpaired Student’s t-test).

134

While the memory TCD8+ cells that are specific for M158 in HLA-A2+ individuals are
known to predominantly use Vβ17 in their TCR, the immunodominant response to pp65495
derived from CMV does not share this characteristic (61). In fact, the pp65495-specific
TCD8+ in HLA-A2+ humans has been shown to use a large variety of different Vβ regions,
many of which cannot bind SEB. CMV is another virus for which specific immunity can
be found in most individuals, as most North Americans have been exposed to the virus in
early childhood. If possession of an SEB-reactive Vβ region is what drives the SEBinduced expansion of M158-specific TCD8+, then the pp65495-specific TCD8+ should show
no such response. Three healthy donors that have both detectable populations were bled
and PBMCs were isolated, stimulated with SEB and stained as in the other human PBMC
experiments. The only change was the inclusion of staining on each day for pp65495specific cells as well as those that are M158-specific. As anticipated, the M158-specific
population was expanded by contact with SEB (Fig. 32A) while the pp65495-specific
population was not (Fig. 32B). These data strongly suggest that the expansion of the M158specific population was due to the expression of a Vβ17+ TCR.
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Figure 32. SEB induces expansion of M158-specific TCD8+ but not memory TCD8+
specific for CMV-derived pp65495. PBMCs were harvested from healthy donors and
cultured as in Figure 29. Surface and tetramer staining was carried out as in Figure 29 as
well, save for the inclusion of the CMV pp65495-specific tetramer. Each point shows data
from one sample harvested from in vitro culture. Data from each donor is stacked in vertical
columns and is collected from the same experiment. (A) The effect of SEB versus PBS on
the expansion by fold change of M158-specific TCD8 per day from three healthy human
donors. (B) The effect of SEB versus PBS on the expansion by fold change of pp65 495specific TCD8+ per day from the same three healthy human donors, run in parallel.
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As is the case in the mouse system, expansion of human TCD8+ does not necessarily
correlate with increased effector function. It is possible that the M158-specific cells are
expanded by SEB but remain anergic to stimulation by cognate peptide. To address this,
PBMCs from three healthy human donors were isolated and cultured with SEB as in
Figure 30 for 11 days. The cells were then stained with the M158-specific tetramer
conjugated to Alexa Fluor 647 before isolation of tetramer+ cells using magnetic labelling
and separation. These purified M158-specific cells were then used as effectors in a
chromium release assay. Briefly, effector cells were incubated with a target cell line that
was pulsed with the peptide of interest (in this case M158) and labelled with radioactive
chromium. The effector cells were then incubated with the target cells at different ratios
for a set amount of time, and specific killing of the target cells was measured by the
release of chromium into the supernatant. As a control for background killing the effector
cells were also incubated with labelled target cells that had not been pulsed with peptide.
For all three donors the data show that M158-specific TCD8+ that have been treated with
SEB are capable of specifically killing target cells pulsed with cognate peptide, and that
the amount of killing positively correlates with increasing effector:target cell ratios (Fig.
33). These data show that the M158-specific population that have been expanded by
contact with SEB are functional, rather than being anergic or exhausted.
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Figure 33. M158-specific TCD8+ from three healthy donors that have been incubated
with SEB display the ability to kill target cells pulsed with M158 peptide. Target cells
consisted of the HLA-A2+ cell line T2 pulsed with M158 peptide. After adding the target
cells to the effectors killing was allowed to proceed for 8 hours, followed by collection of
the culture supernatants that were evaluated for radioactive chromium content using a
gamma radiation counter. Data for each donor (flow plots and percent specific killing) is
shown stacked in vertical columns. Points correspond to mean ±SD of technical replicates,
with N=4 for Donor 7 and N=3 for Donor 6 and Donor 1 (*, p<0.05, **, p<0.01 and ***,
p<0.001, unpaired Student’s t-test).

See Figure 29A
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Chapter 4: Discussion
In this work, we have shown that the effect of bacterial superantigens on epitope-specific
TCD8+ responses is markedly different than what had been previously reported with
respect to the effect of SAgs on bulk TCD8+ responses (1, 2, 3, 4). Though the ability to
detect splenic TCD8+ bearing SEB-reactive Vβ regions through surface staining for TCRVβ is indeed diminished (after a three-day stimulation in vitro), our data suggest that this
is likely due to SAg-induced activation and the resultant TCR internalization rather than
deletion or anergy of the responding cells. Using a mouse model of IAV vaccination in
conjunction with administration of SAgs, we have shown that bacterial SAg can actually
be used to boost primary epitope-specific TCD8+ responses to IAV, though the timing of
SAg administration is crucial in the context of the recall response. In addition, the SAgboosted epitope-specific TCD8+ have enhanced effector function as measured by their
ability to kill peptide-pulsed target cells in an in vivo killing assay. However, despite the
ability of SAg to induce systemic effects on the immune system, SEB injected into the
peritoneal cavity has no effect on local responses to i.n. IAV infection. Returning to our
investigation in the vaccination model of IAV exposure, we found that bacterial SAg also
enhanced memory response to IAV vaccination in terms of magnitude and effector
function. Furthermore, extension of our work to studies involving human memory TCD8+
specific for IAV revealed that SAg also effectively increases the magnitude and effector
function of pre-existing IAV-specific memory cells in HLA-A2+ individuals rather than
inducing deletion or anergy.
Previous studies focused on the effects of SAg on T-cell responses have often examined
TCD4+ cells, with the effect of TCD8+ somewhat relegated to a secondary concern (4, 5).
Most studies focusing on TCD8+ also relied on the use of surface markers or tetramers to
detect the cells (2, 6), which can be problematic given the ability of certain bacterial SAg
to induce TCR internalization (7, 8). Indeed, we observed a loss of detectability when using
α-Vβ Abs or tetramers to detect the presence of TCD8+ at early time points after SEB
administration or exposure. Our use of an ICS as the primary method for the detection of
epitope-specific TCD8+ responses circumvents this problem by relying on the expression
of intracellular IFNγ in lieu of TCR on the surface. In addition, our study is the first to
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examine the effect of SAg on many different epitope-specific TCD8+ responses
simultaneously, allowing us to examine the relative effects of SAg-induced changes on the
ID hierarchy. Our choice of a BALB/c mouse model was also fortuitous as BALB/c mice
possess increased sensitivity to SEB in comparison with other mouse strains (9), without
the morbidity upon SAg injection into humanized mice (10). This enabled us to dissect
changes to the TCD8+ ID hierarchy in detail without the confounding effects of weight loss
or cytokine storm among other deleterious effects of SAgs.
The initial result of enhanced responses to select TCD8+ epitopes in SEB-treated mice in
the context of the primary response to IAV vaccination (Fig. 3) was unexpected. This was
because the in vitro data generated by us (Fig. 2) and other groups showed contraction of
SAg-stimulated cells after an initial period of proliferation. In addition, clinical evidence
of immune suppression after human exposure to bacterial SAg (such as that after the
resolution of sepsis) also led us to expect an immunosuppressive effect of SAg in our model
(11, 12). This may still be true in certain contexts, but our results demonstrate that careful
evaluation of experimental methods, timing and doses is necessary to isolate the effect of
a given SAg on a defined set of TCD8+ responses.
We showed that administration of SEB before vaccination with IAV increased the
magnitude of the TCD8+ response to select IAV-derived epitopes (Fig. 3). This increase
was noted in the local response to IAV in the peritoneal cavity, as well as the systemic
response to IAV as measured in the spleen. This experimental setup was designed so that
IAV was introduced into the mice at the peak of SEB-induced proliferation (13). Prior to
SEB exposure, these mice are known to have a pool of naïve TCD8+ clones specific for
IAV-derived epitopes (14). The naïve cells specific for NP147 and HA518 are able to bind
and be activated directly by SEB, as these clones likely possess Vβ regions sensitive to
SEB, as demonstrated by our Vβ profiling experiments during the primary response. It is
possible that these clones are expanded by SEB, and that introduction of IAV into the
system via vaccination acts to boost proliferation of these populations. This model would
explain why administration of SEB before immune contact with IAV leads to expansion of
epitope-specific populations bearing SEB-reactive Vβ regions while other populations
(such as TCD8+ specific for PB2289) are not significantly expanded over the analogous
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population in PBS-injected control mice. Another possibility is that SEB remains in the
peritoneal cavity and blood until after administration of IAV, augmenting the proliferation
of select IAV-specific clones. This scenario is highly unlikely, as SEB rapidly binds
receptors in vivo (15, 16).
Despite the inherent problems with detection of epitope-specific TCD8+ with tetramers
after contact with SAg, we wanted to ensure that the IFNγ+ cells detectable by ICS
represented the whole population of epitope-specific TCD8+, not just those that are capable
of expressing IFNγ. We reasoned that SAg-induced down-regulation of the TCR would not
be an issue at the time point examined, 10 days after initial contact with SAg. Our tetramer
staining experiments agreed well numerically with the data obtained from ICS, suggesting
that the population identified in the ICS experiments represents the total respective epitopespecific populations (Fig. 7). It may also be worthwhile to confirm this by performing an
intracellular stain with tetramer, though my previous experiments with MHC I tetramer
have shown this to be a difficult and time-consuming experiment to optimize.
The question of why some epitope-specific TCD8+ populations display preferential use of
certain Vβ regions remain unanswered by our study, though Vβ region analysis of the
NP147- and HA518-specific responses suggest that possession of SAg-reactive Vβ regions
enables their selective expansion (Fig 13). Data from human studies of the M158-specific
TCD8+ response in HLA-A2+ individuals, which largely use the Vβ17 region in their TCR,
shows that this Vβ selection is driven by binding efficiency to cognate peptide:MHC I
complexes (17). Selection of the Vβ17 region results in a TCR with a relatively flat surface
around the peptide-binding groove, which facilitates interaction with a comparatively large
variety of peptide:MHC complexes (18). A similar phenomenon could be driving restricted
Vβ region selection for the NP147- and HA518-specific TCD8+ responses in the BALB/c
mouse model.
Our experiments with the SAgs MAM and SEA reinforce the conclusion that selective
expansion of the NP147- and HA518-specific responses are driven by SAg-reactive Vβ
expression. We were fortunate to find a mouse-adapted SAg that could bind Vβ8, namely
MAM (19, 20). A repeat of the same primary experiment that had been performed with
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SEB revealed similar expansion of the Vβ8-bearing NP147- and HA518-specific populations
(Fig. 14). It is interesting to note how similar the effect on the IAV-specific response was,
given that SEB is derived from Staphyloccoccus and MAM is produced by a completely
unrelated Mycoplasma. This suggests that the main determinants of the SAg-mediated
effect are the characteristics of the T cell population that is capable of being bound by the
SAg. Accordingly, even though SEA is derived from the same bacterial species as SEB,
there was no effect on the NP147- or HA518-specific TCD8+ responses (Fig. 15), as SEA is
incapable of binding Vβ8 (21).
Reversing the order of IAV and SEB administration shows that the enhancement of IAVspecific TCD8+ responses is not confined to one particular experimental schedule. Rather,
vaccination with IAV before exposure to SEB either 4 (Fig. 16) or 7 (Fig. 17) days later
produced significantly enhanced responses in terms of the magnitude for most epitopespecific TCD8+ populations, even those (such as cells specific for PB2289) that do not
predominantly express SAg-reactive Vβ regions. In this case SEB is boosting immune
responses to IAV that are already underway, so that the cells are in a state of proliferation
rather than resting. The effect of SEB on the kinetics of the primary TCD8+ response to
IAV as elucidated during our time-course experiments may also shed some light on why
these later experiments, those reversing the order of IAV and SAg administration, show
increases in the epitope-specific populations that are not tied to Vβ expression. At later
time points, such as day 9 and 11 after IAV injection, we observed that the PB2289-specific
population has started to expand significantly in the SEB-treated mice compared to the
PBS controls. This later expansion could be the result of proliferation induced by the
production of cytokines by SEB-responsive populations (22, 23). This same cytokine
production could be driving the significant increases in most populations of IAV-specific
TCD8+ observed in the IAV-before-SEB experiments. A good follow-up experiment to test
if this is indeed the case would be to delete all SEB-reactive TCD8+ from the mouse system
and inject the animals with SEB to see if any IAV-specific populations are expanded.
Alternatively, NP147-specific TCD8+ could be isolated from SEB-injected mice and
cultured with PB2289-specific cells to see if the latter population expands. This setup is
technically easier and potentially less problematic than deleting SEB-reactive cells in vivo,
though it is a more artificial system.
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Our functional readouts of TCD8+ ability show that SEB increased the effector capability
of TCD8+ as well as the magnitude of this response. CD107a detection assays showed that
after simulation with peptide, more TCD8+ positive for IFNγ and CD107a were detectable
in the SEB-treated mice as compared to PBS-treated mice (Fig. 9). This suggests that SEB
does not impair the ability of TCD8+ to degranulate in response to IAV and actually
increases the abundance of the population that is able to do so. Interestingly, there was a
trend towards decreased amount of CD107a expression per cell on TCD8+ from SEBinjected mice, although the difference was small and not statistically significant for most
peptides. If this trend is biologically meaningful it is possible that contact with peptide
subsequent to activation by SEB leads to activation-induced cell death at least in some
cases, causing a selective loss of the highest CD107a expressers (24). However, if this is
taking place the number of cells thus affected must be small, as the total number of epitopespecific CD107a+ cells is still increased in the SEB-injected mice.
The in vivo killing assays in SEB- versus PBS-injected mice showed that SEB significantly
enhanced IAV-specific killing in a more biologically relevant readout of TCD8+ effector
function than in vitro degranulation assays (Fig. 10). This enhancement was detectable in
both the SEB-before-IAV and the IAV-before-SEB primary response models. As part of
the in vivo killing assay, virus-specific cells in the spleen of the SEB injected mice must
recognize their cognate peptide in the context of MHC I and kill their target, as would occur
in the case of natural infection with IAV. Unfortunately, this assay cannot distinguish
whether or not SEB increases the killing ability of TCD8+ on a per cell basis (i.e. whether
SEB enhances “serial killing” by TCD8+ (25, 26)) and/or whether the increased killing is a
product of increased numbers of virus-specific cells in the spleen.
Our next set of experiments was aimed at examining how the strain of IAV used for
vaccination may influence how TCD8+ react to SEB. Different strains of IAV are known
to induce different CD8+ T cell responses in terms of magnitude and peptide recognition
(27). Examples from cases of human infection include the relatively modest immune
responses to the 2009 pandemic H1N1 compared to the massive immune activation seen
during the 1918 Spanish flu pandemic (28, 29). We used four different strains of IAV, two
artificially modified in the lab (J1, X31) and two derived from naturally circulating strains
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(NT60, HK) to address this. All four strains have a core derived from PR8, so any epitopes
derived from the interior proteins of the virus (NP, PB2) will be identical to those derived
from PR8 (30, 31). This enabled me to detect TCD8+ specific for these epitopes via ICS
using PR8-derived epitopes that we have available. We found that the effect of SEB on
virus-specific TCD8+ was the same for cells elicited in response to vaccination using all
four viruses as compared to the response to PR8 vaccination (Fig. 11). The relatively more
modest magnitude of the TCD8+ responses elicited by vaccination with the naturallyderived NT60 and HK strains can likely be explained by the fact that these viruses are not
mouse-adapted and thus less immunogenic in mice (32). It would also be interesting to
perform this experiment with an IAV strain that encodes a highly cytotoxic version of the
PB1-F2 protein. PB1-F2 induces cell death (33), and the expression of a particularly
virulent version may tip the balance in SEB-activated cells from activation to anergy.
Our next step was to see if SEB had the same effect on TCD8+ specific for IAV when IAVderived peptides were presented in the context of an unrelated virus. We used two strains
of rVV that encode NP147 and HA518, respectively, as ES minigenes (34). This allowed me
to examine the effect of SEB on TCD8+ specific for the vaccinia and IAV epitopes
simultaneously. In addition, expression of NP147 and HA518 as ES minigenes bypasses TAP
pathway by fusion of the immunogenic peptide to an endoplasmic reticulum targeting
sequence (35). This increases the antigenicity of the expressed peptides so that robust
TCD8+ responses can potentially be measured (36). This experiment also allowed me to
examine the effect antigen presentation pathway may have on how SEB-stimulated TCD8+
respond to their cognate peptide, as rVV minigenes are usually presented through direct
priming while IAV-specific responses arise through a mix of cross-priming and direct
priming (37, 38, 39). Interestingly, we found that the TCD8+ response to rVV as well as
the encoded IAV-derived epitopes was significantly decreased in the SEB-injected
animals. Another important difference between IAV and rVV that could have influenced
our results is that while i.p. injection of IAV does not result in viral replication (40), i.p.
injection of rVV does (41). This could affect antigen availability as well as causing a loss
of certain cell types due to virus-induced cell death in the case of rVV injection (42). To
address these possibilities, follow-up experiments should include a time course for the
effect of SEB on the kinetics of the virus-specific TCD8+ response, similar to what we have
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done for IAV vaccination. In addition, a repeat of this primary experiment should be carried
out in female mice to allow enumeration of viral titres in the ovaries (43) in order to gain
a clearer picture of whether the presence of SEB could have an indirect effect on viral
replication.
Our investigation into the effect of SEB on the TCD8+ response to active viral infection
also yielded somewhat unexpected results. Previous studies have shown that administration
of SEB intranasally can be highly lethal (44), and that injection of SEB at certain times
during the response to IAV infection can result in significant mortality as well (45).
Combined with evidence showing that injection of SEB i.p. can induce lung pathology
(46), I decided on an i.p. route of SEB administration for use in our mouse model of IAV
infection. I also chose to use a sub-lethal dose of IAV in order to be able to harvest lung
tissue and BAL from mice at the peak of the TCD8+ response to i.n. IAV, which is after
peak mortality (47). Monitoring of the infected mice revealed no difference in weight loss
induced by SEB administration, with or without IAV infection (Fig. 23). Analysis of the
TCD8+ response by IAV-derived epitope via ICS also showed no changes in the lungs or
cells retrieved from the airways via bronchoalveolar lavage (Fig. 24). Interestingly, the
systemic effect of SEB on IAV-specific TCD8+ was still detectable in the spleen. At the
sites of viral replication in the lungs and airway, it could be that the induction of other cells
that play a role in the response to IAV (such as macrophages and NK cells (48, 49)) may
be producing enough inflammatory mediators that drown out the effect of SEB. It may be
possible to magnify any SEB-induced changes to lung TCD8+ by directly instilling SEB
into the airway, but this is likely to produce mortality before the peak TCD8+ responses to
IAV are reached. We also examined the effect of SEB on lung viral titres at their peak on
day 4 after infection, but no significant differences were detected (Fig. 25 and 26). A
follow-up experiment would be to see if clearance of the virus from the lungs is enhanced
or delayed in the SEB-injected animals.
The effect of SEB on the recall response to IAV in the context of a prime-boost vaccination
regimen was particularly interesting for its revelation of the importance of timing with
regards to the effect of SEB on TCD8+ responses. Elevated numbers of KLRG1- CD127+
memory precursors among epitope-specific TCD8+ after the primary response in SEB-
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injected animals (Fig. 19) suggested that recall responses to IAV may be augmented by
SEB administration before the priming injection. Accordingly, mice were injected with
SEB three days before priming with IAV i.p. One month later the mice were boosted with
an i.p. dose of IAV (SEQ.12) before assessment of the secondary IAV-specific response
after one week. As expected, the response to the IAV-derived epitopes that had been
expanded during the primary response was elevated in the SEB-treated mice (Fig. 20).
However, injection of SEB three days before the boosting dose of IAV resulted in a
diminished TCD8+ response to all IAV-derived epitopes (Fig. 21). These cells expressed
decreased levels of Ki67 and increased expression of Fas and LAG3 relative to cells from
PBS-injected mice (Fig. 22). In this case, SEB may indeed be inducing deletion or anergy
of virus-specific TCD8+. This could be due to the timing of the SEB and IAV doses; at day
27 the IAV-specific TCD8+ are still in the contraction phase of the primary response to
IAV. They then receive a strong proliferative signal from SEB binding, quickly followed
by stimulation with their cognate antigen. This series of stimuli could result in activationinduced cell death, accounting for the decreased numbers and Ki67 expression along with
the increased expression of anergy and exhaustion markers. Future experiments should
focus on the comparison of TCD8+ populations just prior to boosting or priming, since
these results suggest that naive T cells react differently to SEB than those remaining after
the primary response.
Given the different results obtained from experiments with SEB administration during the
recall response, we asked how memory cells specific for IAV react to SEB stimulation. We
induced IAV-specific memory in mice by injecting the animals with IAV two months
before injection with SEB. Three days after SAg administration we examined the
percentage and numbers of epitope-specific TCD8+ by ICS. In the spleens of the SEBtreated animals we found that that the percentage and number of cells specific for every
IAV-derived epitope was significantly increased in the SEB-injected mice, though we
focussed our attention on the NP147-specific response as it is the most immunodominant
peptide and showed the greatest augmentation (Fig. 28). In addition, an in vivo killing assay
examining the effect of SEB on the cytotoxic ability of these NP147-specific cells showed
dramatically increased killing of NP147-pulsed splenocytes in the SEB-injected animals
(Fig. 29). These results encouraged the investigation of the effect of SEB on IAV-specific
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memory TCD8+ in humans, as the likelihood of an individual having developed anti-IAV
immunity at some point in their life is very high (50).
Studies have shown that most individuals with an HLA-A2+ haplotype will direct most of
their IAV-specific TCD8+ immune response against the M158 peptide (51). The relative
abundance of the HLA-A2 haplotype among individuals of Caucasian descent also make
the TCD8+ response against this epitope an attractive choice for human IAV studies (52).
We obtained blood from healthy HLA-A2+ donors, isolated PBMCs by Ficoll density
gradient centrifugation and cultured these cells for 11 days in the presence or absence of
SEB. On days 0, 4, 7 and 11 we stained the samples from each condition with M158-specific
tetramer to enumerate IAV-specific memory TCD8+ (Fig. 30). For donors with a detectable
population on day 0, we found that this population “disappeared” in terms of tetramer
staining on day 4. We continued to follow this population in culture on day 7 and finally
on day 11. On both days we detected expansion of these IAV-specific memory TCD8+,
which suggests that our failure to detect them on day 4 was the result of TCR internalization
rather than deletion. In addition, we found that this expansion was likely due to the
predominant expression of Vβ17 in the M158-specific TCR (53), a Vβ region that is bound
by SEB in humans (54). We tested this by repeating the culture experiment with the MAM
SAg, which also binds human Vβ17 (55), and noticed the same expansion trend as for SEB
(Fig. 31). This shows that the ability to enhance the magnitude of human memory TCD8 +
to IAV is not confined to a SAg from a single microbial species. To further examine the
role of Vβ in augmentation of human memory antiviral responses by SAg, we chose to test
the effect of SEB on a memory population that did not predominantly express an SEBreactive Vβ region. Human memory TCD8+ specific for pp65495, the immunodominant
epitope derived from CMV in HLA-A2+ individuals, is made up of a collection of cells that
vary in their Vβ expression (56, 57). Comparison of the effect of SEB on M158-specific
versus pp65495-specific cells from the same donors showed that SEB induced expansion of
the former population while the latter remained relatively unchanged (Fig. 32). This further
suggests that the Vβ composition of IAV-specific TCD8+ in HLA-A2+ individuals renders
these populations especially susceptible to SAg-induced skewing.
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Finally, we tested the effect of SEB on the ability of human M158-specific TCD8+ to kill
targets pulsed with cognate peptide. Since injecting SEB into humans and performing in
vivo killing assays in humans are obviously out of the question, we isolated PBMCs from
HLA-A2+ donors and cultured them in the presence of SEB for 11 days. On the final day,
we harvested the cells and isolated M158-specific TCD8 for use as effector cells in a
chromium release assay. For each of the three donors we recruited, the SEB-treated cells
displayed effective specific killing of their peptide-pulsed targets after 8 hours of
incubation (Fig. 33). This level of killing was significantly increased over unpulsed
controls, showing that SEB was not inducing the TCD8+ to indiscriminately kill any target
cell.
Taken together, the results from the mice and human experiments revealed a possible role
for bacterial SAg as a possible adjuvant for future IAV vaccines once their deleterious
effects can be minimized. They can be used to boost responses to IAV-derived epitopes
while conserving the ability of these cells to kill their cognate targets. Though the current
vaccines against IAV rely on induction of strong Ab responses, this defence strategy only
works for IAV strains for which we can formulate a preventative vaccine. Optimal defence
against primary IAV infection with novel strains relies on effective TCD8+ responses (58,
59), which can be boosted through therapeutic vaccination. Given the recent emergence of
several novel highly pathogenic strains of IAV and the increasingly rapid spread of
pandemic IAV strains around the globe (60), formulation of new therapies to boost TCD8+
responses against IAV is becoming imperative. My research also helps us to better
understand the interactions between bacterial SAgs and IAV infection in terms of the
impact on the antiviral TCD8+ response. Since the co-occurrence of infection by SAgproducing bacterial strains and IAV remains a significant clinical problem (61, 62),
understanding the effect of this interaction on the immune system could lead to better
treatments for cases of bacterial-viral coinfection.
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